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Abstract 
 
The transcription factor Pax8 is expressed during thyroid development 
and is involved in the morphogenesis of the thyroid gland and maintenance of 
the differentiated phenotype. To date, Pax8 has been shown to regulate all the 
genes that are considered markers of thyroid differentiation. To identify novel 
Pax8 target genes we performed a genome-wide expression analysis following 
Pax8 siRNA. The silencing of Pax8 expression in rat thyroid differentiated 
FRTL-5 cells and the subsequent analysis of the gene expression profile by 
microarray identified Wnt4 among the down-regulated genes. As the other 
members of the Wnt family, Wnt4 has been implicated in several 
developmental processes including regulation of cell fate and patterning during 
embryogenesis. Up to now, the only data on Wnt4 in thyroid concern its down-
regulation as necessary for the progression of thyroid epithelial tumors. 
Currently, we believe that it could be involved in thyroid morphogenesis, 
development and in the maintenance of the epithelial phenotype. 
We focused our attention on the elucidation of the molecular mechanisms by 
which Pax8 could regulate Wnt4 expression in thyroid cells. Analysis of the 5’-
flanking region of the Wnt4 gene identified a putative Pax8 binding site 
confirmed by EMSA and ChIP analysis. Moreover, transfection of FRTL-5 
cells with different regions corresponding to progressive deletions of the 5’-
UTR of Wnt4 showed that all the generated constructs possess a thyroid-
specific activity due to the presence of the transcription factor Pax8 and other 
transcription factors recently demonstrated to be its interactors. The results 
obtained during this study show that Pax8 is indeed involved in the 
transcriptional modulation of the Wnt4 promoter. Interestingly, we also 
revealed that the expression of Wnt4 is TSH dependent in FRTL-5 cells. 
Taken together, our data indicate that in thyroid cells the transcription factor 
Pax8 participates to Wnt4 gene expression directly binding to its 5’-flanking 
region suggesting that Wnt4 is a new target of this master regulatory gene. We 
propose that in thyroid cells the expression of Wnt4 correlates with the 
integrity of the epithelial phenotype and is reduced when this integrity is 
perturbed. Moreover, we would like to suggest that the over-expression of 
Wnt4 in thyroid cancer cellular models is able to revert the mesenchymal 
phenotype. 
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1. BACKGROUND 
 
1.1 Introduction 
 
Wnts are powerful regulators of cell proliferation and differentiation, 
and their signaling pathway involves proteins that directly participate in both 
gene transcription and cell adhesion (Nelson and Nusse 2004). Over the past 
two decades, 19 members of the Wnt protein family have been found in 
mammals and have been subdivided into canonical signaling, with 
transforming activities in mammary epithelial cells, and non canonical 
signaling involved in the planar cell polarity (PCP) and in Calcium signaling 
(Eisenmann 2005). 
Member of the Wnt family, Wnt4 is classified as a non-canonical Wnt protein 
even though there is evidence that it is also able to activate the canonical 
signaling pathway (Li et al. 2013). Wnt4 knockdown highlighted its crucial 
role in the development of several organs such as kidney, ovary and mammary 
gland (Brisken et al. 2000; Vainio et al. 1999). Moreover, Wnt4 null mice die 
within 24h of birth, probably because of severe lack of kidney functions (Stark 
et al. 1994). In kidney development, Wnt4 plays a key role in the mesenchymal 
to epithelial transition and morphogenesis required for tubule formation 
(Tanigawa et al. 2011) and is activated by the transcription factor Pax2 that is 
expressed during normal kidney development and is able to influence 
outgrowth and branching of the ureteric bud (Torban et al. 2006). Interestingly, 
the clinical and molecular features of the SERKAL syndrome have been 
identified as associated with a homozygous null mutation in WNT4 in humans, 
demonstrating that this gene plays an essential role in human sex-determination 
and organogenesis (Mandel et al. 2008). 
Moreover, Wnt4 was shown to be strongly down-regulated in human anaplastic 
carcinomas and to behave as a key factor in Ras-mediated transformation of rat 
epithelial cells (De Menna et al. 2012). 
We recently observed that the silencing of the transcription factor Pax8 in 
FRTL-5 differentiated thyroid cells and the subsequent analysis of the gene 
expression profile identifies Wnt4 among the down-regulated genes defining 
Wnt4 as a novel target of this transcription factor (Di Palma et al. 2011). Pax8, 
a member of the Pax genes family, is expressed almost exclusively in thyroid 
and kidney (Plachov et al. 1990; Poleev et al. 1992) and is required for both the 
morphogenesis of the thyroid gland and the maintenance of the thyroid-
differentiated phenotype (Pasca di Magliano et al. 2000). In Pax8 knockout 
mice, the thyroid gland is  barely visible and lacks the follicular cells 
(Mansouri et al. 1998); accordingly the expression of the thyroid specific 
markers, like Thyroglobulin (Tg) and Thyroperoxidase (TPO), cannot be 
detected. All together, the above studies demonstrated that Pax8 plays a crucial 
role in thyrocytes differentiation. Interestingly, mutations in the Pax8 gene 
have been associated with congenital hypothyroidism in humans (Di Palma et 
al. 2000). 
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Here, we investigated the molecular mechanisms by which Pax8 could regulate 
Wnt4 expression in thyroid cells. The bioinformatic (in silico) analysis of the 
5’-flanking region of the Wnt4 gene identified several putative Pax8 binding 
sites and our results show that indeed Pax8 is involved in the transcriptional 
regulation of the Wnt4 gene. Since it is known that the expression of Pax8 is 
inhibited by TGF-β1 treatment of FRTL-5 cells in a concentration dependent 
manner (Kang et al. 2001), we have therefore studied the mechanisms by 
which the over-expression of Wnt4 could prevent the EMT induced by TGF-
β1. Indeed, we show that TGF-β1 treatment is no longer able to induce EMT in 
a cellular model over expressing Wnt4. 
Taken together, our data indicate that in thyroid cells Pax8 participates to Wnt4 
gene expression directly binding to its 5’-flanking region and that the reduced 
expression of Wnt4 correlates with the alteration of the epithelial phenotype. In 
conclusion, we suggest that the over-expression of Wnt4 in thyroid cancer 
cellular models is able to revert the mesenchymal phenotype. 
 
1.2 The Thyroid gland 
 
The thyroid is one of the largest endocrine gland in the body and is 
composed of two cone-like lobes or wings: lobus dexter (right lobe) and lobus 
sinister (left lobe); and it is also connected with the isthmus. The thyroid gland 
is an organ situated on the anterior side of the neck and its name is due to its 
shield shape (from the greek tireòs = shield). (Figure1) 
 
 
Figure 1: Thyroid localization. 
 
In a fully differentiated thyroid we can find two cellular types: the follicular 
cells and the parafollicular cells (De Felice and Di Lauro 2004) (Figure 2). 
 
Trachea 
Thyroid 
Larynx 
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Figure 2: Follicular and parafollicular cells of the thyroid gland. 
 
The follicular cells produce thyroid hormones T3 and T4 while the 
parafollicular cells produce calcitonin. Thyroid hormones are synthesized into 
colloids by iodination and condensation of thyroxin molecules bound to 
thyroglobulin (Tg) by a peptide bond. Tg is a glycoprotein that acts both like a 
substrate for the synthesis of thyroid hormones and as a storage of them. Via a 
reaction with the enzyme thyroperoxidase, iodine is covalently bound to 
tyrosine residues in Tg molecules, forming monoiodotyrosine (MIT) and 
diiodotyrosine (DIT). Thyroxine (T4) is produced by combining two molecules 
of DIT while triiodothyronine (T3) is produced by combining one molecule of 
MIT and one molecule of DIT. (Figure 3) 
 
 
Figure 3: Mechanism of thyroid gland functioning. 
 
Most of the thyroid hormones circulating in the blood is bound to transport 
proteins. Only a very small fraction of the circulating hormone is free 
(unbound) and biologically active, hence measuring concentrations of free 
thyroid hormones is of great diagnostic value. When thyroid hormone is bound, 
it is not active, so the amount of free T3/T4 is what really matters. For this 
reason, measuring total thyroxine in the blood can be misleading. T3 bind 
almost exclusively to Thyroxin Binding Globulin (TBG) while 80% of T4 bind 
to TBG, 15% to Thyroxin Binding Prealbumin (TBPA) and remaining 5% to 
seroalbumin. It is likely that all the cells in the body are targets for thyroid 
Parafollicular 
cells 
Follicular 
cells 
Colloid 
Capillary 
blood 
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hormones. While not strictly necessary for life, thyroid hormones have 
profound effects on many fundamental physiologic processes, such as 
development, growth and metabolism. Thyroid hormones stimulate diverse 
metabolic activities in a lot of tissues, leading to an increase in basal metabolic 
rate. One consequence of this activity is to increase body heat production, 
which seems to result, at least in part, from increased oxygen consumption and 
rates of ATP hydrolysis. Thyroid hormones regulate lipid metabolism; in fact, 
increased thyroid hormone levels stimulate fat mobilization, leading to 
increased concentrations of fatty acids in the plasma. They also enhance 
oxidation of fatty acids in many tissues. Finally, plasma concentrations of 
cholesterol and triglycerides are inversely correlated with thyroid hormone 
levels - one diagnostic indication of hypothyroidism is increased blood 
cholesterol concentration. Thyroid hormone play also a role in the 
carbohydrate metabolism. They stimulate almost all aspects of carbohydrate 
metabolism, including enhancement of insulin-dependent entry of glucose into 
cells and increased gluconeogenesis and glycogenolysis to generate free 
glucose. 
Thyroid hormones are clearly necessary for normal growth in children and 
young animals, as evidenced by the growth-retardation observed in thyroid 
deficiency. Not surprisingly, the growth-promoting effect of thyroid hormones 
is intimately intertwined with that of growth hormone, a clear indication that 
complex physiologic processes like growth depend upon multiple endocrine 
controls. Also it is of critical importance in mammals the fact that normal 
levels of thyroid hormone are essential to the development of the fetal and 
neonatal brain. Thyroid hormones also acts on the cardiovascular system where 
they increases heart rate, cardiac contractility and cardiac output. They also 
promote vasodilatation, which leads to enhanced blood flow to many organs, 
like for example: the central nervous system, in which both decreased and 
increased concentrations of thyroid hormones lead to alterations in mental state 
(too little thyroid hormone, and the individual tends to feel mentally sluggish, 
while too much induces anxiety and nervousness); the reproductive system in 
which normal reproductive behaviour and physiology is dependent on having 
essentially normal levels of thyroid hormone (hypothyroidism in particular is 
commonly associated with infertility). The thyroid gland is under the control of 
the pituitary gland, a small gland the size of a peanut at the base of the brain. 
When the level of T3 and T4 drops too low, the pituitary gland produces 
Thyroid Stimulating Hormone (TSH) which stimulates the thyroid gland to 
produce more hormones. Under the influence of TSH, the thyroid will 
manufacture and secrete T3 and T4 thereby raising their blood levels. The 
pituitary senses this and responds by decreasing its TSH production. The 
pituitary gland itself is regulated by another gland, known as the hypothalamus. 
The hypothalamus is part of the brain and produces TSH Releasing Hormone 
(TRH) which tells the pituitary gland to stimulate the thyroid gland by 
releasing TSH. (Figure 4) 
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Figure 4: Schematic representation of the axis Hypothalamus-Pituitary gland-Thyroid. 
 
1.3 Gene expression regulation and thyroid-enriched transcription factors 
 
Gene expression includes all the events that go from the transcription of 
a gene to the production of the corresponding protein. All these events are 
finely regulated. Studying gene expression means to understand in which tissue 
a gene is expressed, how it is expressed and what causes its expression. In fact, 
phenotypic differences among different cell types are mainly due to differences 
in gene expression patterns. Gene expression can be regulated at different 
levels: activation of DNA structure, start of transcription, maturation of the 
transcript, transport into the cytoplasm, translation of mRNA and protein 
stability. Nevertheless, the most important step is the start of the transcription 
process which determines whether a gene is transcribed or not. RNA 
polymerase II, as well as RNA polymerase I and III, needs proteins to find the 
right transcription start site and these proteins necessary for the start of the 
transcription process are called general initiation factors. Given that RNA 
polymerases and general initiation factors are the last targets of regulatory 
events, during the assemblage of the RNA polymerases complex there are 
several points for regulation to take place. It is important to note that purified 
RNA polymerases and corresponding general initiation factors have an 
intrinsic ability to accurately transcribe DNA templates through core promoter 
elements, thus allowing the fundamental transcription mechanisms to be 
elucidated, but these activities are generally suppressed in the cell by the 
packaging of DNA within chromatin and by negative cofactors that directly 
interfere with the function of the basal transcription factors. As discussed 
below, this imposes requirements for transcriptional activators and 
corresponding cofactors that act in a gene-specific manner both to reverse the 
repression (anti-repression) and to effect a net activation above the intrinsic 
activity of the basal transcription machinery.  
It is possible to subdivide transcriptional factors that cooperates directly with 
RNA polymerase II in three different categories:  
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a. general transcription factors;  
b. upstream transcription factors;  
c. inducible transcriptional factors.  
a. General transcription factors are necessary for the start of RNA synthesis in 
all the genes of class II (genes that encodes for proteins). They form a complex 
with the RNA polymerase II close to the transcription start site and this 
complex is called basal complex of transcription. 
b. Upstream transcriptional factors are proteins that recognize short consensus 
sequence situated upstream the transcription start site (an example is the Sp1 
factor that recognizes GC boxes). These factors are ubiquitous and they act 
increasing the transcription efficiency of all the genes containing a GC box in 
their promoter.  
c. Inducible transcriptional factors work like upstream factors, but they have a 
regulatory role. They are synthesized or activated in a tissue-specific manner 
and they recognize sequences called response elements. 
In general, transcription factors acts directly recognizing specific and well 
conserved cis-sequences situated in promoters or enhancers. Some of these 
factors and of these sequences are common to more than a promoter and they 
are used in a constitutive manner; some other are specific and their activity is 
finely regulated. During the assembly process of these factors onto the 
regulatory sequences there are a lot of checkpoints and the speed of 
transcription can be increased or decreased in response to different regulatory 
signals. Nevertheless, not all the transcription factors bind these specific 
sequences on the promoter, they can also recognize other proteins already 
bound to the promoter, and sometimes they can bind directly to the RNA 
polymerase. Often DNA-binding factors that regulate the transcription of 
protein-coding genes act together with an expanding group of cofactors that act 
either through modifications of the chromatin structure or, more directly, 
regulating formation or function (transcription initiation or elongation) of the 
pre-initiation complex. Requirement for cofactors involved more directly in 
transcription is somewhat surprising in view of the specificity intrinsic to the 
various DNA-binding regulatory factors, the structural complexity of their 
ultimate target (the basal transcription machinery), and documented 
interactions between regulatory factors and components of the basal 
transcription machinery. Early studies of activator functions in systems 
reconstituted with DNA templates and purified RNA polymerase II and 
corresponding general initiation factors revealed that additional ‘‘co-activator’’ 
or ‘‘mediator’’ activities were required for the activator function but not for 
basal (activator-independent) transcription. Co-activators function in a variety 
of ways and often contain the enzymatic activities necessary for an alteration in 
chromatin structure from a quiescent state to one allowing active gene 
transcription. Broadly speaking, co-activators can be divided in three classes. 
One class of proteins modifies histones in ways that allow greater access of 
other proteins to the DNA. Examples of these are p300 and CBP, powerful 
histone acetyltransferases (HATs) that interact with a wide variety of 
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transcription factors and other proteins (Hermanson et al. 2002). These proteins 
support transcription in vitro from chromatinized templates. A second class of 
co-activators are members of the TRAP/DRIP/Mediator/ARC complex, 
proteins that bind to transcription factors, recruit RNA polymerase II and 
interact with the general transcription apparatus. The Mediator complex 
supports transcription in vitro from DNA templates but does not support 
efficient transcription from chromatinized templates. Lastly, protein complexes 
of the yeast SWI/SNF family (or their mammalian homologs BRG1 or BRM) 
contain ATP dependent DNA unwinding activities, necessary for efficient gene 
transcription in vivo. These groups of proteins will not support transcription 
from naked DNA, but raise transcription from chromatinized templates in vitro 
(Lemon et al. 2001). Co-repressors have the opposite effect on chromatin 
structure, making it inaccessible to the binding of transcription factors or 
resistant to their actions. These proteins (such as NcoR) are often associated 
with histone deacetylase (HDAC) activity, though other mechanisms for gene 
silencing clearly exist (Hermanson et al. 2002). Although co-activators are 
defined as proteins that increase transcriptional activity without binding to 
DNA, it is useful to think of those that bind directly to transcription factors and 
contain relevant enzymatic activities as primary co-activators. Those that dock 
on transcription factors and serve as scaffolds for the recruitment of other 
proteins containing these enzymatic activities can be considered secondary co-
activators. This distinction rapidly blurs as proteins that can function as 
primary co-activators on some transcription factors can also be used as 
enzymatic tools assembled by secondary co-activators in other contexts. The 
expression of thyroid-specific proteins is responsible for the characteristic 
phenotype of the differentiated thyroid follicular cell. The promoter region of 
the thyroid markers Thyroglobulin (Tg), Thyroperoxidase (TPO), symport 
sodium-iodine (NIS) and TSHr has been characterized and it is known, at least 
in part, the mechanism responsible for their transcriptional activation in thyroid 
cells. The promoter region that allows the thyroid-specific transcription of the 
Tg gene is located between bases -170 and +1 with respect to the start site of 
transcription (Damante and Di Lauro 1994; Sinclair et al. 1990). In particular, 
the promoter region of the Tg gene presents three binding sites for the 
transcription factor TTF-1, which are located in three regions named A, B and 
C: the region A and region C are essential for promoter activity. In the region 
C, besides to the binding site for TTF-1 there is also a binding site for the 
transcription factor Pax8 which physically overlaps that one for TTF-1 
(Zannini et al. 1992). In the region A, the binding site of a ubiquitous protein 
(UFA, ubiquitous factor A) overlaps with TTF-1; less relevant is the function 
of the region B (Sinclair et al. 1990). Between the regions B and C is placed 
the region K, which presents the binding site for the transcription factor Foxe-1 
(Figure 5). 
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Figure 5: Organization of the Tg gene promoter. 
 
The organization of the promoter of the TPO gene is very similar to the 
promoter of the Tg gene; in fact, it presents, three binding sites for TTF-1 in 
regions A, B and C. In the region C the binding site for Pax8 overlaps with the 
binding site for TTF-1, while in region B the binding site of a ubiquitous 
protein (UFB, ubiquitous factor B) overlaps with of TTF-1. The binding site 
for Foxe1 is located in the region Z located between the regions B and C 
(Francis-Lang et al. 1992) (Figure 6). 
 
 
 
 
 
 
 
Figure 6: Organization of the TPO gene promoter. 
 
The expression of characteristic markers of the differentiated thyroid 
phenotype is guaranteed by the presence of three transcription factors thyroid-
specific, essential for the correct development of the thyroid gland: TTF-1, 
Foxe1 and Pax8. These factors, individually, are also present in other tissues 
both embryonic and adult, but their co-expression is observed only in thyroid 
cells mature and its precursors; it has been demonstrated that these 
transcription factors are essential for the expression of the thyroid 
differentiation markers, such as the thyroglobulin (Tg), the thyroidperoxidase 
(TPO), the symport sodium-iodine (NIS) and the TSH receptor (TSHr). 
 
TTF-1/Titf1, also named T-EBP or Nkx2.1, is a member of the Nkx-2 
subfamily, originally identified as a protein able to bind to a DNA sequence 
that is present three times on both the Tg and the TPO promoters, and it is 
involved in the activation of thyroid-specific gene expression. TTF-1 is also 
expressed in the lung, and its presence is required for the transcriptional 
activation of surfactant proteins A, B, and C and Clara secretory protein. The 
critical role of TTF-1 for both thyroid and lung morphogenesis was clarified in 
TTF-1 null mice that resulted not viable and lacked the thyroid, the pituitary 
gland and the lung parenchyma. Deep study revealed that in these mice at the 
begin of the embryogenesis the thyroid primordium forms in its correct 
position, but subsequently, the thyroid precursor cells undergo apoptosis 
(Kimura et al. 1999) and disappear at E10.5–11.5. During mouse development 
TTF-1 expression starts at day E8.5 in endodermal cells that later will become 
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the pharynx and its onset clashes with the proliferation of the cells of the 
endodermal layer. This event is the first step of the development of the thyroid.  
 
Foxe-1 is a member of FOX (Forkhead box) proteins which are a family of 
transcription factors that play important roles in regulating the expression of 
genes involved in cell growth, proliferation and differentiation. FOX proteins 
are able to bind DNA through the forkhead domain that is a domain common 
among several transcription factors involved in development and 
differentiation. In the mouse, Foxe-1 expression starts at 8 dpc into the 
endodermal cells of the pharynx and it is more evident in the posterior area of 
the pharynx, where TTF-1 is not expressed. Hence, this expression pattern 
suggests that Foxe-1 has a less important roles during the first steps of 
development whereas it is very important for the migration of the thyroid gland 
during embryogenesis. In fact, the analysis of Foxe1 knock-out mice revealed 
that thyroid starts to develop normally but, at day E10.5, the thyroid 
primordium fails to migrate towards its correct position in front of the trachea 
attached to pharyngeal endoderm suggesting that Foxe-1 might be important 
during the migration of the thyroid during its development, probably regulating 
the expression of genes involved in cellular migration. 
 
1.4 The transcription factor Pax8  
 
Pax8 is a member of the Pax gene family, a family of genes that 
encodes for DNA binding proteins involved in the regulation of the 
development of a variety of tissues in different species. The Pax gene family is 
composed of nine proteins highly conserved in vertebrates and all these 
proteins are characterized by the presence of the paired box. This specific 
sequence encodes for the paired domain, a very important domain for 
recognizing the target sequences on DNA. The paired domain is composed of 
128 amino acids and is subdivided in two fundamental sub domains, one at C-
terminus the other at N-terminus, called PAI and RED respectively. Each of 
these domains contain an helix-turn-helix motif and both domains are united by 
a linker region (Mansouri et al. 1998) (Figure 7). 
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Figure7: Schematic structure of the protein Pax8. 
 
We can explain the subdivision of the paired domain into two independent 
domains with the ability of Pax proteins family to bind DNA in different ways 
and overall to recognize a lot of sequences. Within the homology rate of the 
paired domains we can subdivide the nine Pax proteins in different groups. One 
of these groups is composed by Pax2, Pax5 and Pax8. These three proteins are 
characterized also by the presence of an octapeptide and a partial 
homeodomain. During embryonic development Pax8 is expressed in thyroid, 
kidney and the nervous tissue. Pax8 has been demonstrated to be required both 
for the morphogenesis of the thyroid gland and for the maintenance of the 
thyroid-differentiated phenotype.  
In the endoderm Pax8 mRNA is present only in the thyroid anlage (Plachov et 
al. 1990). Like Titf1/Nkx2-1, Pax8 is detected in the developing thyroid from 
E8.5, i.e., at the time of specification. 
Expression of Pax8 is maintained in TFCs during all stages of development and 
in adulthood. In the nervous system, Pax8 mRNA is transiently expressed in 
the myelencephalon and through the entire length of the neural tube. No signals 
are detected in the brain at later stages of the development, nor are they present 
in the adult brain. In the excretory system, Pax8 mRNA is present in the 
nephrogenic mesenchyme, which gives rise to the epithelial structures of 
nephrons as a consequence of the instructive interactions of the growing 
nephric duct and ureter. Indeed, Pax8 mRNA is expressed in the nephrogenic 
cord at E10.5, in mesenchymal condensations at E13, in the cortex of the 
metanephros at E16, and in the adult kidney. 
Analysis of Pax8
-/-
 mice revealed the role of this transcription factor during 
embryonic life. Whereas no phenotype has been detected in heterozygous 
Pax8
+/- 
mice, homozygous Pax8
-/-
 mice are born at the expected Mendelian 
frequency but show growth retardation and die within 2–3 wk. These mice do 
not display any apparent defects in the spinal cord, midbrain/hindbrain 
boundary, or kidneys. On the contrary, in Pax8
-/-
 mice the thyroid gland is 
severely affected because neither follicles nor TFCs can be detected, and the 
rudimentary gland is composed almost completely of calcitonin-producing C 
cells. Hypothyroidism is the cause of death of the mutated animals: the 
administration of T4 to Pax8
-/-
 mice allows the animals to survive.  
PAIRED DOMAIN 
OCTAPEPTIDE 
PARTIAL 
HOMEODOMAIN 
TRANSACTIVATION 
DOMAIN 
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In addition, important roles in morphogenesis of the TFC component of the 
thyroid gland, it has been shown, in cell culture systems, that Pax8 is a master 
gene for the regulation of the thyroid-differentiated phenotype (Pasca di 
Magliano M. et al. 2000). Pax8 not only is required for the survival of the 
thyroid precursor cells but also holds a specific upper role in the genetic 
regulatory cascade, which controls thyroid development and functional 
differentiation. These functions of Pax8 in thyroid development are consistent 
with the findings that in other organs Pax genes have a relevant role both in 
initiating and maintaining the tissue-specific gene expression program (De 
Felice and Di Lauro 2004).  
 
1.5 Wnt proteins 
 
The WNT genes encode for a large family of secreted glycoproteins highly 
conserved among species. During development, Wnts have different roles in 
several biological processes as cell fate, stem cell maintenance, proliferation, 
migration, polarity, and death. In adults, Wnts function in homeostasis, and 
inappropriate activation of the Wnt pathway is implicated in a variety of 
cancer.  The majority of WNT proteins share a sequence identity of 35% there 
are though different subgroups that share even higher grade of sequence 
identity (58% - 83%). The 19 human WNT protein so far identified have 
different common features like: very similar size within a range of 39 kDa – 46 
kDa, a secretory signal at the N-terminus, several highly charged amino acids 
residues and many glycosilation sites (Miller 2001 and Clevers 2006). 
Moreover, WNT glicoproteins share a 23 or 24 cysteine residues sequence 
evolutionarily conserved, suggesting that Wnt proteins folding depends on the 
formation of multiple intramolecular disulfide bonds. The primary amino acid 
sequences of these proteins suggest that they should be soluble instead secreted 
Wnts are highly hydrophobic and strictly associated at the extracellular matrix 
and cell membrane. The high hydrophobicity of these proteins is due to 
palmytolation of the first cysteine residue and of a serine residue in the middle 
of the protein. In fact, although Wnt proteins are secreted from cells, secretion 
is usually inefficient and previous attempts to characterize Wnt proteins have 
been hampered by their high degree of insolubility (Willert et al. 2003 ). Once 
palmytolated in the endoplasmatic reticulum, Wnt proteins are transported and 
secreted in vesicles. Once secreted the extracellular trafficking of Wnt proteins 
is mediated by large lipoproteins present on the external face of plasma 
membrane. (Hausmann et al. 2007) (Figure 8). 
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Figure 8: Schematic representation of Wnt secretion. 
 
1.6 Wnt signaling 
 
Wnt signaling is transduced through binding with different receptors. 
The most studied are the Frizzled proteins, which are seven transmembrane 
receptors with an extracellular N-terminal rich domain (CRD). Another 
important regulator of Wnt signaling, is the LDL receptor related proteins 5/6 
(LRP5/6) that acts promoting the WNT/Fz binding. (Kikuchi et al. 2007). 
Through the binding with a complex comprised by Frizzled and LDL receptor-
related proteins 5/6 (LRP5/6) Wnt proteins are able to activate canonical 
signaling instead the binding with Fz, Ryk, or Ror2 preferentially activates 
non-canonical pathways. The canonical pathway is mainly involved in cell fate 
determination, differentiation  and stem cell renewal while the non-canonical 
one is responsible of morphological changes and tissue organization (Figure 9). 
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Figure 9: Outline of the Wnt signaling pathway. 
 
The best known Wnt pathway is the Wnt/β-catenin pathway also defined 
"canonical" Wnt signaling (Figure 10). The signaling function of β-catenin is 
regulated principally through alteration of its stability. Wnt signalling induces 
the stabilization of the ‘free’ cytoplasmic pool of β-catenin. In the absence of 
Wnt signaling, β-catenin is rapidly degraded by a destruction complex 
consisting of APC, axin (conductin homolog), glycogen synthase kinase 3-beta 
(GSK3β) and casein kinase (CKI). CKI and GSK3b induce the phosphorylation 
of β-catenin. Thus, The phosphorylated β-catenin is linked to ubiquitination 
and proteosomal degradation. Wnt proteins bind to Fz and LRP5/6 activate the 
cytoplasmic protein DVL (Dishvelled) that subsequently recruits the complex 
APC/axin/CKI/GSK3β to the cell membrane. β -catenin is so allowed to 
accumulate in the cytosol. Once in the cytosol β-catenin can either associate 
with E-cadherin mediating cell adhesion (Brembeck et al. 2006) or translocate 
to nucleus were in collaboration with T-cell factor (TCF) and lymphoid 
enhancer-binding protein transcription factor (LEF) activates target genes 
transcription. 
 
 
Figure 10: Wnt canonical signaling and dual function of  β –catenin. 
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The non-canonical pathway involves the signalings mediated by Wnt without 
β-catenin. The Planar Cell Polarity (PCP) pathway is considered as non-
canonical pathway. In vertebrate, Wnt/polarity signalling is thought to control 
polarized cell movement during gastrulation and neurulation. Another non-
canonical way through which Wnt proteins can act is the Ca
2+
 dependent 
pathway (Kohn et al. 2005). This signalling involves an increase in 
intracellular Ca
2+ 
and activation of PKC. It could be activated by a distinct 
group of ligands and Fzd receptors; at first, the Wnt/Ca
2+
 pathway involves 
activation of  a heterotrimeric G protein, an increase in intracellular Ca
2+ 
and 
activation of calcium/calmoduline-regulated kinase II (CamKII) and PKC. 
(Schlessinger et al. 2008) (Figure 11). 
 
 
Figure 11: A proposed Wnt/GTPase pathway. 
 
The non-canonical pathways can act through different cellular mechanisms 
such as the inhibition of the canonical pathway, the regulation of cell migration 
and cell polarity. The complexity of the Wnt pathway is constantly increasing 
thanks to discoveries of novel receptors and co-receptors able to transduce Wnt 
signaling.  
 
1.7 Wnt4 
 
Wnt4 is a member of the Wnt family and is common classified as a 
non-canonical Wnt protein even though it has been demonstrated that it is also 
able to activate the canonical signaling, depending on the cellular context 
(Schlessinger et al. 2009). Wnt4 null mice die after birth probably for severe 
kidney dysfunctions (Stark et al. 1994). More in details, female mice lacking 
Wnt4 show a regression of the Mullerian duct, partial female to male sex 
reversal and oocytes degeneration (Vainio et al. 1999). At early stage of 
development Wnt4 is expressed in both female and male gonad and after sex 
determination Wnt4 is down-regulated in the male: this event is needful to 
induce Mullerian duct regression and to allow the blood coleomic vessel 
formation, a vasculature structure characteristic of male gonads. (Jeays-Ward 
et al. 2003). Interestingly, Wnt4 plays a key role in the mesenchymal to 
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epithelial transition and morphogenesis required for tubule formation in kidney 
development (Vainio et al. 2003).  
To date, it has been described only an autosomal recessive disorder caused by a 
loss of function mutation in Wnt4 gene named SERKAL Syndrome (Mandel et 
al. 2008). In particular, this syndrome is characterized by different overlapping 
features including female sex reversal and dysgenesis of kidneys, adrenals and 
lungs. The Wnt4 missense mutation associated with this syndrome was shown 
to adversely affect mRNA stability, most probably as a result of distruption of 
a highly conserved mRNA secondary structure. Defective Wnt4 activity was 
found to affect the development of three major organs (gonads, kidneys, and 
adrenal glands), all of which originate from the primordial urogenital ridge, 
thus suggesting a pivotal role for Wnt4 at an early embryological stage of 
development. More specifically, the authors suggested that WNT4 suppresses 5 
α-reductase activity in humans. The most important role of 5 α-reductase in 
humans is the conversion of testosterone to 5 α-DHT, which is much more 
potent than testosterone and is responsible for the morphogenesis of the human 
male external genitalia.  
Unfortunately, Mechanisms underlying the regulation of Wnt4 expression in 
thyroid during development are complex and have not been defined in their 
molecular details.  
The only available information concern the identification of  Wnt4 as a key 
player in Ras-mediated 
transformation of rat thyroid epithelial cells, being involved in the inhibition of 
aberrant motility of neoplastic cells (De Menna et al. 2012). In particular these 
data indicate Wnt4 is strongly down-regulated in human anaplastic carcinomas 
thus suggesting that Wnt4 could be involved in advanced human thyroid 
cancer.  
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2. Aims of the study 
 
Transcriptional regulation is a fundamental process for cellular 
differentiation and development.  
In an adult organism differentiated cells are characterized by the expression of 
a specific subset of genes and this expression is regulated mainly at the 
transcriptional level. A good model for studying transcriptional regulation is 
represented by thyroid follicular cells that express a very specific set of genes, 
called differentiation markers, that are thyroglobulin (Tg), sodium-iodide 
symporter (NIS), thyroperoxidase (TPO) and TSH receptor (TSHr). 
The most important transcription factor for the development and the 
differentiation of thyroid follicular cells is Pax8 (Pasca di Magliano et al. 
2000). In this context, Pax8 interacts with another crucial transcription factor, 
TTF-1, and these two factors are able to synergistically induce the expression 
of the thyroglobulin gene (Di Palma et al. 2003). Moreover, Pax8 and TTF-1 
are part of an heterocomplex that has an apparent molecular mass greater than 
the sum of the two factors suggesting the presence of other co-factors. 
The silencing of Pax8 expression in thyroid differentiated FRTL-5 cells 
recently generated in our laboratory and the following analysis of the gene 
expression profile by microarray indicated Wnt4 among the down regulated 
genes (Di Palma et al. 2011).  
Wnt4 was initially classified as a non-canonical Wnt protein, but more recently 
it has been described to activate also the canonical signaling pathway. Wnt4 
knockdown underlined its crucial role in the development of several organs 
such as kidney, ovary and mammary gland.  
Interestingly, recent data have been demonstrated that Pax2, another member 
of the Pax gene family, is able to activate Wnt4 promoter activity in a proximal 
tubule cell line promoting nephrogenesis (Torban et al. 2006).  
We focalized this research project on the study of the role of the Wnt4 gene in 
correlation with the transcription factor Pax8 in thyroid differentiated cells and 
the possible involvement of Wnt4 in human thyroid tumors.  
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3. Materials and methods 
 
3.1 RNA interference 
 
FRTL-5 cells were plated (8x10
4
 well) in a 24-well plate and were 
transfected in triplicate with 50 nM rat Wnt4 siRNA (Ambion, Life 
Technologies Ltd, UK), 100 nM Pax8 siGENOME siRNA or siGENOME 
Non-Targeting #3 (Dharmacon, Lafayette, CO) as scramble using 
DharmaFECT 1 transfection reagent, following the manufacturer’s protocol. 72 
h after transfection, the cells were harvested and the total RNA was extracted. 
 
3.2 RNA extraction, cDNA synthesis and quantitative real-time PCR 
  
Total RNA was prepared using TRIzol Reagent (Invitrogen, San Diego, 
CA) according to the manufacturer’s directions. Total RNA (1 μg) was 
retrotranscribed using the iScript cDNA Synthesis kit (Bio-Rad Laboratories). 
Real-time PCR analysis was performed using an iCycler-iQ real-time detection 
system and SYBR green chemistry (Bio-Rad Laboratories). To design the 
qRT-PCR assays, we used the Primer Express software, and the primers 
sequences are:  
 
Rat 
Oligonucleotides 
Sequence 
Act Fw 5’-GGCAATGAGCGGTTCCGATG-3’ 
Act Rw 5’-ATGGTGGTGCCACCAGACAG-3’ 
Pax8 Fw 5’-CAGCTATGCCTCTTCCGCTATT-3’ 
Pax8 Rw 5’-TGTGGCTGTAGGCATTGCC-3’ 
Wnt4 Fw 5’-TCCTCGTCTTCGCCGTGTTC-3’  
Wnt4 Rw 5’-GAGCTTCTCGCACGTTTCCTC-3’ 
E-cadh Fw 5’-CCTGGGACTCCAGTTACAGG-3’ 
E-cadh Rw 5’-CTCAGACCCTGTGAAAGCTGG-3’ 
α-SMA Fw 5’-ACAATGGCTCCGGACTGGTG-3’ 
α-SMA Rw 5’-AGAGTCAGGATGCCTCGCTTG-3’ 
Vim Fw 5’-GAATACCGGAGACAGGTGCAG-3’ 
Vim Rw 5’-CGGCCAATAGTGTCCTGGTAG-3’ 
Snail I Fw 5’-GATGCACATCCGAAGCCACAC-3’ 
Snail I Rw 5’-GGAGCAGGAGAAAGGCTTCTC-3’ 
Fbn Fw 5’-CTACCAAGGCTGGATGATGGTGG-3’ 
Fbn Rw 5’-GGAGCAGGTTCCCTCTGTTG-3’ 
 
 
 
 
 22 
HUMAN 
Oligonucleotides 
Sequence 
GAPDH Fw 5’-GTCTTCACCACCATGGAGAA-3’ 
GAPDH Fw 5’-ATCCACAGTCTTCTGGGTGG-3’ 
Pax8 Fw 5’-CCCTTCCAACACGCCACT-3’ 
Pax8 Rw 5’-CTGCTTTATGGCGAAGGGTG-3’ 
Wnt4 Fw 5’-CATGAGTCCCCGCTCGT-3’ 
Wnt4 Rw 5’-CGAGTCCATGACTTCCAGGT-3’ 
E-cadh Fw 5’-CGAGAGCTACACGTTCACGG-3’ 
E-cadh Rw 5’-CTTTGAATCGGGTGTCGAGGG-3’ 
α-SMA Fw 5’-ACAATGGCTCCGGACTGGTG-3’ 
α-SMA Rw 5’-AGAGTCAGGATGCCTCGCTTG-3’ 
Vim Fw 5’-CGGGAGAAATTGCAGGAGGAG-3’ 
Vim Rw 5’-CAAGGTCAAGACGTGCCAGAG-3’ 
Snail I Fw 5’-GATGCACATCCGAAGCCACAC-3’ 
Snail I Rw 5’-GGAGCAGGAGAAAGGCTTCTC-3’ 
Fbn Fw 5’-AGCGGACGCATCACTTGCAC-3’ 
Fbn Rw 5’-TGCACTGGAGCAGGTTTCCTC-3’ 
 
Reactions were carried out in duplicate in three independent experiments. For 
each gene, values are means ± SD of three independent experiments, 
normalized by the expression of housekeeping gene, and expressed as a 
percentage of the value measured in parental FRTL-5 or BcPAPcells. To 
calculate the relative expression levels, we used the 2
-
DDCT method (Livak 
and Schmittgen 2001) 
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3.3 ChIP assay 
 
Genomic sequences including 3 kb upstream of the start codon were 
retrieved from Genome website (http://www.genome.ucsc.edu) and were 
explored to predict potentially transcription factor binding sites using GEMS, 
Genomatix software (http://www.genomatix.de). Chromatin 
immunoprecipitation (ChIP) was performed as follows. The cross-linking 
solution, containing 1% formaldehyde, was added directly to cell culture 
media. The fixation proceeded for 10 min and was stopped by the addition of 
glycine to a final concentration of 125 mM. FRTL-5 cells were rinsed twice 
with cold PBS plus 1 mM PMSF, and then scraped. Cells were collected by 
centrifugation at 800xg for min at 4 C. Cells were swelled in cold cell lysis 
buffer containing 5 mM piperazine-N,Nbis (2-ethanesulfonic acid) (pH 8.0), 85 
mM KCl, 0.5% Nonidet P-40, 1 mM PMSF, and inhibitors cocktail (Sigma) 
and incubated on ice for 10 min. Nuclei were spun down by 
microcentrifugation at 2000xg for 5 min at 4 C, resuspended in nuclear lysis 
buffer containing 50 mM Tris-HCl (pH 8), 10 mM EDTA, 0.8% sodium 
dodecyl sulfate (SDS), 1 mM PMSF and inhibitors cocktail (Sigma), and then 
incubated on ice for 10 min. Samples were broken by sonication into chromatin 
fragments of an average length of 500/1000 bp and then microcentrifuged at 
16,000xg. The sonicated cell supernatant was diluted 8-fold in ChIP Dilution 
Buffer containing 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
Tris-HCl (pH 8.1), and 167 mM NaCl, and precleared by adding Salmon 
Sperm DNA/Protein A Agarose (Upstate Biotechnology, Inc., Lake Placid, 
NY) for 30 min at 4 C. Precleared chromatin from 1x10
6
 cells was incubated 
with 1 mg of affinity-purified rabbit polyclonal antibody anti-Pax8 (kindly 
provided by Prof. R. Di Lauro), or no antibody and rotated at 4 C for 16 h. 
Immunoprecipitates were washed five times with RIPA buffer containing 10 
mM Tris-HCl (pH 8), 1 mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 
0.1% SDS, 140 mM NaCl, and 1 mM PMSF; twice with LiCl buffer containing 
0.25 M LiCl, 1% Nonidet P-40, 1% Na-deoxycholate, 1 mM EDTA, 10 mM 
Tris-HCl (pH 8.0), and then three times with TE (10 mM Tris-HCl, pH 8; 1 
mM EDTA). Before the first wash, the supernatant from the reaction lacking 
primary antibody was saved as total input of chromatin and was processed with 
the eluted immunoprecipitates beginning at the cross-link reversal step. 
Immunoprecipitates were eluted by adding 1% SDS, 0.1 M NaHCO3 and 
reverse cross-linked by addition of NaCl to a final concentration of  200 mM 
and by heating at 65 C for 16 h. Recovered material was treated with 
proteinase K, extracted with phenol-chloroform-isoamyl-alcohol (25:24:1) and 
precipitated. The pellets were resuspended in 30 μl of TE and analyzed by PCR 
using specific primers for the analyzed regions. The input sample was 
resuspended in 30 μl of TE and diluted 1:10 before PCR. 
PCR was performed using the following specific primers: Forward, 5’-
GATCCAGAAGCGAGGTTTCGGAT–3’ and Reverse, 5’–
AACCTAGTCACTAGCGCTCGGG-3’. 
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3.4 Promoter constructs and plasmids 
 Specific proximal promoter fragments of rat Wnt4 gene were amplified 
by PCR using the following primers: 
 
Construct name Oligo Forward Oligo Reverse 
3100Wnt4LUC 5’-CGACGCGTAGCCTCCCTGCCTTTGGCCC-3’ 5’-GGAAGATCTGGTGCCGTGGGTGTCCGCCC-3’ 
920Wnt4LUC 5’-CCGCTCGAGACAGAAAGGCGAGGGGTTCA-3’ 5’- CCCAAGCTTGGTGCCGTGGGTGTCCGCCC-3’ 
640Wnt4LUC 5’-CCGCTCGAGGCTCTCGCTCCGGTGGCT-3’ 5’- CCCAAGCTTGGTGCCGTGGGTGTCCGCCC-3’ 
300Wnt4LUC 5’-CCGCTCGAGGGGGGGGGTGTCCCGCGCC -3’ 5’- CCCAAGCTTGGTGCCGTGGGTGTCCGCCC-3’ 
190Wnt4LUC 5’- CCGCTCGAGGCTGACAGTCGGGTCCGTCG-3’ 5’- CCCAAGCTTGGTGCCGTGGGTGTCCGCCC-3’ 
 
The 3100Wnt4LUC was cloned into MluI/BglII sites of the pGL3basic vector 
(Promega, Madison, WI) , while all the other construct were subcloned into 
XhoI/HindIII of the same vector. 
Wnt4 cDNA (NCBI Reference Sequence NM_005923) was obtained by PCR 
from mouse thyroid cDNA using the forward primer 5'-
CGGAATTCCGGGAGCCTTGCGGCCGCTG-3' and the reverse primer 5'-
GCTCTAGATCACCGGCACGTGTGCATCT-3'. Wnt4 cDNA was digested 
with EcoRI and XbaI restriction enzymes and cloned in both pCEFL Puro 
vector carrying puromycin resistance. 
CMV Pax8 construct was already described (Zannini et al. 1992). 
 
3.5 Cell culture and transfection assays 
 
Rat thyroid follicular FRTL-5 cells were maintained in Coon’s 
modified F12 medium (EuroClone, MI, Italy) supplemented with 5% newborn 
bovine serum (HyClone, Logan, UT), penicillin and streptomycin 100X 
(EuroClone, MI, Italy), 20ng/ml Glycyl-histydyl-lysine (Sigma-Aldrich, St. 
Louis, MO), 3.6ng/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO), 
10μg/ml bovine pancreas insulin (Sigma-Aldrich, St. Louis, MO, USA), 
5μg/ml Apo-Transferrin Human, 10ng/ml Somatostatin (Sigma-Aldrich, St. 
Louis, MO, USA) and 0.5mU/ml thyroid stimulating hormone (TSH). 
The starvation medium consisted of Coon’s modified Ham’s F12 medium 
supplemented only with 0,2% BSA. TSH treatment was performed by addition 
of 1 mU/ml TSH (Sigma-Aldrich, St. Louis, MO) to the culture medium at 12, 
24, and 48 h after starvation.  
HeLa cells and BcPAP cells were grown in DMEM (EuroClone) supplemented 
with 10% vol/vol fetal calf serum (HyClone). NIH3T3 cells were grown in 
DMEM (EuroClone) supplemented with 10% newborn bovine serum 
(HyClone, Logan, UT).  
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Transfections were carried out with the FuGENE 6 reagent (Roche 
Diagnostics, Munich, Germany) according to the manufacturer’s directions. 
The DNA/FuGENE ratio was 1:3 in all the experiments. 
The plasmid pRL-TK (Promega) was used as internal control in the 
transfection assays. Cells extracts were prepared 48 h after transfection to 
determine the levels of the firefly and renilla luciferase with the Luciferase and 
Renilla Reporter Assay System (Promega).  
48h after transfection cells were lysed in Passive lysis buffer (Promega 
Corporation, Madison, WI, USA) supplemented with 100X protease inhibitors 
(Sigma-Aldrich, St. Louis, MO, USA). Firefly and renilla luciferase activity 
were assayed, respectively, with the Luciferase Assay System (Promega 
Corporation, Madison, WI, USA) and the Renilla Assay System (Promega 
Corporation, Madison, WI, USA) following manufacturer’s instructions. 
Luminescence was measured with LUMAT LB 9507 luminometer (Berthold 
Technologies, Bad Wildbad, Germany). Firefly luciferase activity was 
normalized on the activity of TK-Renilla vector to correct each sample for 
transfection efficiency. Transfection experiments were done in duplicate and 
repeated at least three times. 
 
3.6 Electrophoretic mobility shift assay (EMSA) 
 
Double-strand oligonucleotides were labeled with γ-32P ATP and T4 
polynucleotide kinase and used as probes. The binding reactions were carried 
out in a buffer containing 20 mM Tris-HCl (pH 7.6), 75 mM KCl, 1 mM 
dithiothreitol, 10% glycerol, 1 mg/ml BSA, and 3 mg/ml polydeoxyinosinic 
deoxycytidylic acid. After 30 min of incubation at room temperature, free 
DNA and DNA-protein complexes were resolved on a 6% non denaturating 
polyacrylamide gel and visualized with a by autoradiography. 
The oligonucleotides used in the competition assay and the antibodies used in 
the supershift experiments were incubated with the protein extract for 20 min 
before adding the probe. 
Oligonucleotides derived from the MatInspector analysis were: probe A, 5’-
GCGGGTCCAGCGGCGCGGGACACCCCCC-3’ and probe B, 5’-
TCCGCCGCCACCGCCGCATCCCGGCTCTG-3’. The oligonucleotide 
mutated in the core sequence was: 5’-
GCGGGTCCAGCGGATATGGACACCCCCCC-3’. 
 
3.7 Protein extract and immunoblotting 
 
Cells were washed twice with ice-cold PBS and lysed in a buffer 
containing 10 mM HEPES (pH 7.9), 400 mM NaCl, 0,1 mM EGTA (pH 7.8), 
5% glycerol, 1 mM dithiothreitol, and 1 mM phenylmetilsulfonil fluoride. The 
protein concentration was determined using the Bio-Rad protein assay (Bio-
Rad Laboratories, Hercules, CA). 
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For Western blot analysis, proteins were separated on SDSPAGE, and gels 
were blotted onto PVDF membranes (Immobilon-P, Millipore, Bedford, MA). 
The primary antibodies used were: mouse monoclonal anti-Wnt4 (Zymed, 
Invitrogen). Secondary antibody Rabbit IgG Horseradish peroxidase linked 
whole antibody (GE Healthcare) were used as suggested by manufacturers. 
The filters were developed using an enhanced chemiluminescence detection 
method (Pierce, Rockford, IL) according to the manufacturer’s directions. 
 
3.8 TGF-β1 treatment 
  
FRTL-5, FRTL-5 Wnt4 cl 31 and FRTL-5 Wnt4 cl 35 cells were 
cultured in complete medium. At 70% of confluence, 5 and 10 ng/ml of TGF-
β1 (SIGMA) was added to culture media for 48 hours. RNA was subsequently 
isolated for q-RTPCR experiments.  
 
3.9 Wound-healing assay 
 
Confluent BcPAP, BcPAPpoolpCEFLpuro and BcPAPpoolWnt4 cells 
plated on tissue culture dishes were wounded by manual scratching with 10-μl 
pipette tip, washed with PBS and incubated at 37 C in complete media. At the 
indicated time points, phase contrast images at specific wound size were 
captured. 
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4. Results and Discussion 
 
4.1 Wnt4 is a novel Pax8 target gene identified in FRTL-5 cells 
 
The differentiation program of thyroid follicular cells (TFCs), by far the 
most abundant cell population of the thyroid gland, relies on the interplay 
between sequence-specific transcription factors and the transcriptional co-
regulators with the basal transcriptional machinery of the cell. However the 
molecular mechanisms leading to the fully differentiated thyrocytes are still the 
object of intense study. The transcription factor Pax8, a member of the Paired-
box gene family, has been demonstrated to be a critical regulator required for 
proper development and differentiation of thyroid follicular cells. Despite 
being Pax8 well-characterized with respect to its role in regulating genes 
involved in thyroid differentiation, genomic approaches aiming at the 
identification of additional Pax8 targets are lacking and the biological 
pathways controlled by this transcription factor are largely unknown. 
Therefore, to identify new downstream targets of Pax8, we investigated the 
genome-wide effect of Pax8 silencing comparing the transcriptome of silenced 
versus normal differentiated FRTL-5 thyroid cells. In total, 2815 genes were 
found modulated 72 hours after Pax8 RNAi, induced or repressed. As shown in 
the volcano plot representation below, red dots represent differentially 
expressed genes and gray dots represent all the other genes (Figure 12). 
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Among the down-regulated genes we identified Wnt4 that belongs to the signal 
transduction category. This gene has been demonstrated to play an important 
role in the development of several organs such as kidney, ovary and mammary 
gland. It has been demonstrated that Pax8 is able to activate Wnt4 promoter 
Figure12: Volcano plot representation of dysregulated genes. 
 The negative log10-transformed p-values are plotted against the log 
ratios (log2 fold change) between conditions. Red dots represent 
differentially expressed genes that show both large fold changes and 
high statistical significance. Gray dots represent all the other genes. 
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activity in a proximal tubule cell line promoting nephrogenesis (Torban et al. 
2006). At the same time, a cooperative role for Pax2 and Pax8 in metanephric 
branching morphogenesis and nephron differentiation has been uncovered 
(Narlis et al. 2007). 
To validate the expression data obtained by the microarray analysis, we 
performed qRT-PCR for Wnt4 on RNA samples prepared 72 h after Pax8 
siRNA transfection. The FRTL-5 cells transfected with a non targeting siRNA 
were used as control. As shown in Figure 13 the down-regulation of Pax8 in 
thyroid cells closely correlates with reduced expression levels of Wnt4. Hence, 
the results of the microarray analysis were validated by the qRT-PCR analysis. 
 
 
 
 
 
 
The effect of Pax8 silencing on Wnt4 expression was also evaluated 24h after 
siRNA transfection. This time point was chosen because the half-life of the 
Pax8 protein was found to be approximately 16 hours.  
These data strongly suggested Wnt4 as a downstream targets of Pax8, in fact 
reduced levels of the transcription factor Pax8 directly correlate with a 
reduction of the levels of the secreted glycoprotein Wnt4. 
 
    Ctrl  Wnt4  Pax8  
Figure 13: Validation of the microarray results by qRT-PCR. 
Relative gene expression in siPax8 transfectants was calculated using 
non-targeting siRNA transfectant control (Ctrl) as reference. 
Differential gene expression in siPax8 vs Ctrl cells, 72 h after Pax8 
silencing: comparison between qRT-PCR and array data. 
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4.2 Analysis of Wnt4 gene 5’-flanking region 
 
To determine whether Pax8 could regulated Wnt4 gene expression by 
directly binding to its regulative genomic sequence, we performed a 
computational analysis using the MatInspector Software 8.0. We searched for 
Pax8 binding sites in a region of about 3000 bp in Wnt4 5’-flanking region, 
and the analysis showed the presence of several Pax8 consensus sequences. 
Through this in silico analysis of the 3000 bp upstream the ATG of the rat 
Wnt4 gene, several putative binding sites for transcription factors of the Pax 
family have been identified, three of which have already been described in 
literature as binding sites of the transcription factor PAX2 expressed in kidney 
(Torban et al. 2006). 
To characterize more in detail the 5’-UTR of Wnt4 and to assess the 
transcriptional activity of this region in thyroid cells, five different regions 
corresponding to progressive deletions of the 5’UTR were subcloned into 
XhoI/HindIII sites of the pGL3-basic vector upstream the luciferase reporter 
gene (Figure 14).  
 
 
 
 
 
 
 
 
Particularly, the deletions were engineered taking into account the position of 
the Pax8 binding sites predicted by the MatInspector software. To verify the 
expression level and tissue specificity of each fragment, the deletion constructs 
were transiently transfected in FRTL-5 thyroid cells, in HeLa and in NIH3T3 
cells. As positive control we used the RSV reporter construct, whose value was 
set at 100% (Figure 15).  
 
Figure 14: pGL3 basic vector used to subclone the 
progressive deletions of the 5’UTR of Wnt4.  
The five different regions corresponding to progressive 
deletions of the 5’UTR were subcloned into XhoI/HindIII sites 
of the pGL3-basic vector in front of a luciferase (luc) cDNA.. 
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Interestingly, the results obtained showed that all the constructs generated have 
the highest activity in thyroid cells. No reduction of the transcriptional activity 
was observed in the -920, -640, -300 deletions and only the smallest construct 
carrying 190 bp of the Wnt4 5’-flanking region showed a strongly reduced 
activity in rat FRTL-5 cells.  
These results suggest that the 5’-flanking region of Wnt4 is transcriptionally 
active preferentially in thyroid cells and prompted us to study the role of Pax8 
in the modulation of Wnt4 expression. 
To this end, we tested the effect of transient Pax8 expression on the Wnt4 
promoter region (300Wnt4LUC and 190Wnt4LUC respectively) by luciferase 
assays. Specifically, we performed transactivation assays in HeLa cells 
transfecting the reporter constructs 300Wnt4LUC and 190Wnt4LUC together 
with increasing concentration of an expression vector encoding Pax8. As 
shown in Figure 16, Pax8 is able to activates transcription from the 
300Wnt4LUC in a dose dependent manner, but not from smallest construct 
190Wnt4LUC.  
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Figure 15: Capacity of the proximal promoter fragments of the Wnt4 gene to induce 
luciferase reporter gene expression. The constructs were transfected into FRTL-5, 
NIH3T3 and HeLa cells. Luciferace enzyme activity was determined as Wnt4 promoter 
region activity. All the constructs generated have the highest activity in thyroid cells. No 
induction of the transcriptional activity was observed in the -920, -640, -300 deletions and, 
only the smallest construct carrying 190 bp of the Wnt4 5’-flanking region showed a 
strongly reduced activity in rat FRTL-5 cells. 
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These results suggest that the region between 300 bp and 190 bp upstream the 
ATG of the Wnt4 gene represents a crucial region for Pax8 regulation of this 
gene.  
 
4.3 EMSA analysis of the predicted binding sites 
 
The in silico analysis by the MatInspector software predicted two 
binding sites for Pax8 within 300 bp and 190 bp upstream the translational start 
site of the Wnt4 gene that we named A and B respectively (Figure 17). 
 
 
 
 
 
 
 
Specifically, site A was identified on the negative strand, while site B was 
identified on the positive strand of the DNA sequence, respectively, positioned 
at -297 and -211 bp from the translational start site (ATG) mapped on the rat 
promoter. The alignment of the core sequence of the two putative Pax8 binding 
sites shows a high grade of conservation among Wnt4 mammalian promoter 
Figure 16: Pax8 activates transcription from the Wnt4 promoter region. HeLa cells were 
transiently transfectated with 300Wnt4LUC and 190Wnt4LUC alone and in combination 
with increasing concentration (100 and 200 ng) of the expression vector encoding Pax8 
(CMV5-Pax8) 48h after transfection the transcriptional activity was determined as the 
firefly over renilla luciferase activity. Data are sxpressed as fold induction over the 
transcription obtained with with 300Wnt4LUC and 190Wnt4LUC, whose values were set at 
1,0. Data are means from three independent experiments, each performed in duplicate.  
 
Figure 17: Putative Pax8 binding sites in the rat Wnt4 promoter 
region. The 300 bp 5’-flanking sequence of the rat Wnt4 gene was 
analyzed with MatInspector software for possible Pax8-binding 
motifs. In orange the two predicted binding sites.  
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regions, highlighting the potential relevance of these sites for the promoter 
activity (TABLE 1). 
 
Species Pax8 predicted binding site A Pax8 predicted binding site B 
Rat TGTCCCGCGCCGCT CCGCCGCCACCGCC 
Mouse TGTCCCACGCCGCT CCGCCGCCACCGCC 
Human TGTCCCGGGCCGCT CCGCCGCCgCCGCC 
Chichen TGTCCCCAGCGGCG                 CCTCCGCT 
 
 
 
 
 
To further characterize and verify the prediction obtained by the MatInspector 
analysis, we designed two oligo probes, containing the putative binding sites A 
and B and we performed gel mobility shift experiments. At first, we incubated 
the A and B 
32
P-labeled oligo probes with total protein extracts prepared from 
FRTL-5 thyroid cells. We used total protein extract of wild-type and Pax8-
transfected HeLa cells, as negative and positive control, respectively. 
Interestingly, the retarded band observed when FRTL-5 protein extract was 
incubated with oligo A (Figure 18, probe A, lane 2) is identical to the retarded band 
of the retarded band of the positive control (Figure 18 probe A, lane 4). In contrast, 
the predicted binding site B could not be confirmed as a Pax8 binding site 
(Figure 18, probe B). 
 
Table 1: Graphic output of the sequence analysis showing the conservation in 
different species of the core consensus sequences (in bold) . 
The sequence alignment was obtained using whole genome comparative analysis from 
VISTA browser 2.0. 
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1: Free probe
2: FRTL-5
3: HeLa
4: HeLa-Pax8
5: FRTL-5 + Ab anti-Pax8
6: FRTL-5 + Ab anti-tubulin
Competitor:
A   A     B
1    2    3   4     1    2   3   4
A   
Oligo A Oligo Amut
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5
X
5
0
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0
0
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X
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0
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1   2 1     2     5      6   
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0
X
2
5
X
5
0
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1
0
0
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Afterwards, we demonstrated by competition assays that the retarded band 
observed when the FRTL-5 extract is incubated with oligo probe A is the result 
of a specific interaction. We tested the binding specificity of the oligo probe A 
by competition with unlabeled oligo A and itself mutated in the core sequence. 
The Pax8 protein complex was specifically inhibited by competition with 25, 
50 and 100 fold molar excess of unlabeled “self” but the competition with the 
cold mutated probe A is completely abolished (Figure 18). 
To further consolidate this data of Pax8 binding on the oligo probe A, we 
performed a supershift assay with an anti-Pax8 specific antibody. This time, as 
shown in Figure 18, lane 5, we observed that a supershifted band is produced after 
the incubation of FRTL-5 protein extract and the probe A with the anti-Pax8 
Figure 18: Electromobility shift assays for Pax8 binding to putative recognition motifs in 
the Wnt4 promoter. 
32
P-labeled oligo probes A and B were challenged in EMSA with total protein extracts 
prepared from FRTL-5 (lane 2). We used total protein extracts of HeLa (lane 3) and Pax8-
transfected HeLa cells (lane 4), as negative and positive control of the EMSA. The specificity 
of the complexes observed with the FRTL-5 protein extract and probe A was tested by 
competition analysis, using an increasing amount (from 25 to 100-fold molar excess) of 
unlabeled oligonucleotides A or unlabeled oligonucleotides A mutated in the core sequence. 
Protein extract of FRTL-5 was incubated, alone or together with the antibody against Pax8 or 
tubulin (as control), in a supershift EMSA with labeled probe A. 
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antibody. The specificity of this supershifted band is confirmed by the presence 
of the expected retarded band corresponding to the Pax8-oligo complex and by 
the absence of a supershift when the FRTL-5 protein extract is incubated with 
the anti-tubulin antibody (Figure 18, lane 6). 
All together, these results demonstrate that Pax8 is able to specifically binds in 
vitro to the sequence identified.  
Furthermore, to demonstrate the ability of Pax8 to interact with the Wnt4 
promoter region in vivo, chromatin immunoprecipitation (ChIP) assays on 
FRTL-5 cells were carried out. The cross-linked chromatin was 
immunoprecipitated using a polyclonal Pax8 antibody. As control, to rule out 
unspecific background of the ChIP assay, one reaction lacking the primary 
antibody was also performed. The successful PCR with specific 
oligonucleotides to amplify the region with more predicted Pax8 binding sites 
upstream the coding sequence, revealed the binding of Pax8 to the 5’-flanking 
region of Wnt4 in vivo (Figure 19). 
 
ChIP
In
p
u
t
P
ax
8
N
o 
A
b
C
on
tr
ol
In
p
u
t
P
ax
8
N
o 
A
b
C
on
tr
ol
 
 
 
 
 
 
 
 
Taken together, the obtained results clearly highlighted that Wnt4 could be 
considered a novel and direct target of Pax8.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19:ChIP experiment for Pax8 binding to Wnt4. Chromatin extracted from cross-
linked FRTL-5 cells was immunoprecipitated using an antibody against Pax8. The 
immunoprecipitated was analyzed by PCR with oligonucleotides corresponding to the rat 
Wnt4 promoter region. Parallel PCR were performed with total input DNA obtained from 
unprecipitated aliquot of similarly treated chromatin sample, an aliquot treated with no 
antibody and from no template control. 
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4.4 Wnt4 is responsible for the maintenance of the epithelial phenotype 
 
The epithelial-mesenchymal transition (EMT) is an orchestrated series 
of events in which cell-cell and cell-extracellular matrix (ECM) interactions are 
altered to release epithelial cells from the surrounding tissue. The cytoskeleton 
is reorganized to confer the ability to move through a three-dimensional ECM, 
and a new transcriptional program is induced to maintain the mesenchymal 
phenotype. Essential for embryonic development, EMT is nevertheless 
potentially destructive if deregulated, and it is becoming increasingly clear that 
inappropriate utilization of EMT mechanisms is an integral component of the 
progression of many tumors of epithelial tissues (Radisky 2005). Induction of 
EMT can compromise the mechanical and physiological integrity of the tissue, 
and inappropriate induction of this process can have disastrous consequences. 
The defining property of cells that undergo EMT – the ability to separate from 
neighboring cells and penetrate into and through surrounding tissues – is 
particularly dangerous when acquired by tumor cells, and EMT processes 
identified in developmental studies are now being found to be involved in key 
steps of tumor metastasis (Kang and Massague 2004; Yang et al. 2004). EMT 
also acts in tumor progression by providing increased resistance to apoptotic 
agents (Maestro et al. 1999; Vega et al. 2004), and by producing supporting 
tissues that enhance the malignancy of the central tumor.  
Recently, Wnt4 has been demonstrated to be essential for normal conversion of 
metanephric mesenchyme to the epithelia of the nephron (Carrol et al. 2005; 
Stark et al. 1994). 
All this evidence prompted us to investigate the involvement of Wnt4 in the 
modulation of the EMT markers. To this end, we silenced Wnt4 with a specific 
siRNA and analyzed by qRT-PCR the expression level of some typical EMT 
markers. The transfection with a siRNA Non-Targeting (siCtrl) was used as 
negative control. More in details, FRTL-5 cells were transfected with siCtrl 
and siWnt4 respectively and 72 hours later, we analyzed the expression level of 
Wnt4, E-cadherin (E-cadh) as epithelial marker and α-Smooth muscle actin (α-
SMA) and Vimentin (VIM) as mesenchymal markers. By qRT-PCR we 
showed that upon Wnt4 knockdown, the mRNA levels of E-cadh are reduced, 
whilst the expression of the mesenchymal markers α-SMA and Vim is up-
regulated in the Wnt4 silenced cells with respect to the FRTL-5 transfected 
with siCtrl (Figure 20). 
 
 
 36 
Wnt4 E-cadh α-SMA Vim
 
 
 
 
 
 
This data demonstrate that reduced levels of Wnt4 correlate with EMT 
suggesting a relevant role of this gene in the maintenance of the epithelial 
phenotype. To better analyze the involvement of Wnt4 in this process, we 
produced stable clones over-expressing Wnt4 in rat thyroid differentiated 
FRTL-5 cells. In particular, we stably transfected the cells with an expression 
vector encoding Wnt4 or with the empty vector as control. The screening 
analysis of all the clones identified two clones, named Wnt4 cl 31 and Wnt4 cl 
35, that express a high level of the exogenous Wnt4 protein (Figure 21).  
 
HeLa
HeLa
Wnt4 FRTL-5 CL1    CL3      CL15     CL 18  CL 29 CL30  CL31  CL33   CL35  
FRTL-5 Wnt4
W.B. αWnt4
 
Figure 21: Wnt4 over-expression in the Wnt4 clones analyzed by Western blot with a specific 
α-Wnt4 antibody. 
Figure 19: Effect of Wnt4 silencing on EMT of thyroid cells.  
qRT-PCR analysis was performed on total RNA prepared from FRTL-5 
transfected either a siRNA ctrl or a siRNA Wnt4. The expression of E-cad, α-
SMA and Vim was measured. 
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To further investigate the role of Wnt4 in the maintenance of the epithelial 
state, we analyzed the same EMT markers described above. As shown in the 
Figure 22 the stable over-expression of Wnt4 is able to revert the mesenchymal 
phenotype. In particular, the up-regulation of this gene determines a strong 
increase of E-cadh and a reduction of the mesenchymal markers (α-SMA and 
VIM). 
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 Figure 22: Effect of Wnt4 over-expression on EMT of thyroid cells. 
qRT-PCR analysis was performed on total RNA prepared from FRTL-5Wnt4 clones 
31 and 35 and from FRTL-5 stable transfected with the empty vector. The 
expression of E-cad, α-SMA and Vim was measured. 
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4.5 The TGF-β1 inducted EMT could be reverted by the over-expression 
of Wnt4 
 
Since many years it has been extensively demonstrated that 
Transforming Growth Factor-β1 (TGF-β1) in thyroid  is a potent inhibitor of 
growth and DNA synthesis in rat (Morris et al. 1988), porcine (Tsushima et al. 
1988), and human (Taton et al. 1993) thyroid follicular cells (TFCs) as well as 
in other epithelial cell systems (Sporn et al 1986; Lyons et al 1990). 
Differentiation markers of TFCs, such as Na
+
/I
-
 symporter (NIS), thyroglobulin 
(Tg), and the TSH receptor (TSHR) are also suppressed by TGF-β1 (Franzen et 
al 1999). TGF-β1 synthesis at the mRNA level has been documented in 
follicular cell cultures derived from the thyroid glands of numerous species 
(Pekary et al 1995). It is also known that the treatment with TGF-β1 of thyroid 
differentiated cells is responsible for a severe reduction of Pax8 expression and 
for the EMT induction. The intringuily ability of TGF-β1 to down-regulate the 
transcription factor Pax8 and to induce EMT, suggested us to investigate a 
possible correlation between low levels of Pax8 induced by TGF-β1 and Wnt4 
expression. 
To investigate this correlation, we treated the FRTL-5 cells with 5 and 10 
ng/ml of TGF-β1 for 48 hours and we analyzed by qRT-PCR the expression 
levels of Pax8, Wnt4 and of specific EMT markers (Figure 23). In agreement 
with the data in the literature, TGF-β1 determines a strong reduction of Pax8 
mRNA level (see panel a) and induces EMT; in addition, this treatment is also 
able to down-regulate the expression level of the epithelial marker E-cadherin 
(panel c), and to significantly induce the levels of its inhibitor Snail I as well as 
of the mesenchymal marker FBN (panels d and e). As expected as a 
consequence of the reduced levels of Pax8, also Wnt4 levels are decreased 
(panel b). 
Subsequently, the two clones over-expressing Wnt4 (Wnt4 cl 31 and 35) were 
treated with the same concentration of TGF-β1 described above. The Wnt4 cl 
31 and 35 that stably over-expressing Wnt4 showed reduced levels of Pax8 and 
endogenous Wnt4 after treatment (panels a and b). Very interestingly, the qRT-
PCR analysis revealed that the over-expression of Wnt4 is able to revert the 
mesenchymal phenotype.  
Notably, the stable exogenous expression of Wnt4 is able to reduce the 
expression of the mesenchymal markers FBN and Snail I (panels d and e), but 
the 48 hours treatment with TGF-β1 is not sufficient to revert the down-
regulation of the E-cadh (panel c). However, the strong reduction the E-cadh 
inhibitor Snail I, an early EMT marker, could suggest that the reversion of the 
mesenchymal state is taking place in the cells that over-express Wnt4.  
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Figure 23: Effect of TGF-β1 on expression of EMT markers. FRTL-5cells and clones 31 and 35 
over-expressing Wnt4 were treated with the indicated concentration of TGF-β1for 48 hours. Total 
RNAs were prepared and analyzed by qRT-PCR for the evaluation of the mRNA expression levels of 
the EMT markers. 
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4.6 TSH regulates Wnt4 expression in thyroid cells 
 
The main physiological stimulus regulating thyroid function is given by 
thyrotropin (TSH) produced by the pituitary gland. Like many other 
hormones, TSH exerts its function through a G protein-coupled receptor, 
the TSH receptor (TSHR), which relies on the associated G protein to 
transmit and amplify the signal inside the cell. In rat thyroid cells, TSH-
mediated activation results primarily in cAMP production that is likely to 
play a crucial role in the onset of diﬀerentiation both in vitro and in vivo. 
Indeed cAMP agonist, for instance forskolin (FSK), can mimic TSH-
induced diﬀerentiation. The presence of TSH is also required for the 
maintenance of the diﬀerentiated phenotype, since withdrawal of TSH for a 
prolonged time causes loss of thyroid-speciﬁc gene expression in cultured 
cells. Several studies have led to the conclusion that TSH regulates the 
expression of the Tg gene by determining its rate of transcription 
(Avvedimento et al. 1984, Van Heuverswyn et al. 1984, Santisteban et al. 
1987). A number of in vitro studies, in which cultured thyrocytes were 
used, have shown that the lack of TSH leads to a drastic reduction of Tg 
mRNA and that re-addition of TSH is able to reactivate Tg transcription 
(Chebath et al. 1979, Tosta et al. 1983). 
In vivo studies in rat models also suggested that TSH controls Tg gene 
transcription via the interaction with its receptor on thyrocytes, and that 
cAMP is a physiological mediator of this eﬀect (Van Heuverswyn et al. 
1984, 1985). However, no cAMP-responsive elements have been found in 
the rat Tg promoter region (Gerard et al. 1989, Lee et al. 1991).  
The thyroid transcription factor Pax8 binds to a single site on the Tg 
promoter, and it has been showed to activate Tg gene expression through a 
thyroid-speciﬁc mechanism (Pasca Di Magliano et al. 2000). In addition, 
Pax8 appears to be also involved in the thyroid-speciﬁc expression of the 
rat sodium/iodide symporter (NIS) gene (Ohno et al. 1999).  
The group where I developed my PhD project investigated the role of Pax8 
as a mediator of TSH action in thyrocytes, demonstrating that in a model 
system of rat thyrocytes in culture in the absence of TSH, Pax8 mRNA and 
protein rapidly disappear, whereas upon TSH stimulation, both mRNA and 
protein are newly synthesized (Mascia et al. 2002) 
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To investigate the role of TSH in the expression of Wnt4, differentiated rat 
thyroid FRTL-5 cells were starved for 7 days in serum-free medium 
containing 0.2% BSA and then treated with TSH for different times (3, 6, 
12, 24 and 48 hours). The expression of both Pax8 and Wnt4 was analyzed 
at the mRNA level by qRT-PCR. As expected, Pax8 expression was 
strongly reduced upon starvation of the cells and reinduced upon TSH 
stimulation. Similarly, also the expression of Wnt4 turned out to be 
modulated by TSH, and the kinetic of induction upon TSH stimulation well 
correlates with that of Pax8, suggesting that TSH regulation of Wnt4 
expression could be mediated by Pax8 (Figure 24).  
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Figure 24: Wnt4 expression is modulated by TSH in FRTL-5 thyroid cells. 
FRTL-5 cells were cultured in regular medium or maintained in starvation 
medium for 7days (T0) and then treated with 1mU/ml of TSH for different times 
(3, 6, 12, 24 and 48h) and analyzed by qRT-PCR analysis to measure the 
expression of Pax8 (gray bars) and Wnt4 (black bars) mRNA.  
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4.7 Wnt4 expression is down-regulated in human thyroid cancer and its 
over-expression is required for cellular migration 
 
Thyroid cancer is the most common malignancy of the endocrine 
system and represents approximately 1% of all newly diagnosed cancer. The 
most frequent type of thyroid malignancy is papillary carcinoma (PTC), which 
constitutes more than 80% of all cases. The overall prognosis of PTC is very 
good with an average 10-years survival rate of more than 90%. However, 
approximately 10% of PTC patients may die as a consequence of their disease. 
Several clinicopathological parameters have been identified to predict a worse 
prognosis including old age at diagnoses, extrathyroidal invasion, distant 
metastases and aggressive histological variants (Miccoli et al. 2009). The most 
recent advances in thyroid cancer research derive from an increased 
understanding of the mechanisms that regulate thyroid cell differentiation and 
proliferation and the signal transduction pathways involved. Among these 
pathways, the Wnt/β-catenin pathway has received most attention during the 
past years for its critical role in cancer (Sastre-Perona and Santisteban 2012). 
Many publications emphasize the role of the Wnt/β-catenin pathway in thyroid 
cancer. Recently it has been showed  that Wnt4 down-regulation is necessary 
for the progression of thyroid epithelial tumors toward a fully malignant 
phenotype (De Menna M. et al. 2012). Moreover, it has been extensively 
demonstrated that a progressive decrease of Pax8 levels occurs in thyroid 
tumors from follicular adenoma to differentiated carcinoma and then to 
anaplastic carcinoma, which parallels the progressive dedifferentiation and 
increasing malignancy of thyroid tumors (Fabbro et al. 1994; 2008).  
To evaluate the involvement of the secreted glycoprotein Wnt4 in thyroid 
carcinogenesis with respect to the transcription factor Pax8, we analyzed (by 
quantitative RT-PCR) both Wnt4 and Pax8 mRNA levels in four different 
human cancer cell lines, derived from follicular (WRO cells), anaplastic (Cal62 
cells) and papillary (FB2 and BcPAP cells) thyroid carcinoma. As control, we 
used a pool of six normal thyroid tissues. As showed in Figure 25 a,  all the 
tested thyroid cancer cell lines express much lower Wnt4 mRNA levels in 
comparison to normal thyroids, indicating that a strong down-regulation of 
Wnt4 expression occurs in thyroid carcinomas.  
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In agreement with the data present in literature, also the mRNA levels of Pax8 
were decreased in the analyzed tumor cancer cell lines. 
Subsequently, to determine whether Wnt4 is able to alter the expression levels 
of the EMT markers, we stable transfected the BCPAP (papillary thyroid 
carcinoma) cell line with an expression vector encoding Wnt4 or with the 
parental vector. We obtained two pools of cells stable transfected with the 
expression vectors pCEFL and pCEFLWnt4, respectively; we analyzed by 
qRT-PCR the expression level of the EMT markers. As showed in Figure 26, the 
over-expression of Wnt4 is able to determine a strong enhancement of E-
cadherin expression in human papillary cancer cells, while no modification is 
observed at the mesenchymal level. The high expression of the E-cadherin, that 
is the main epithelial marker, let us hypothesize that the over-expression of 
Wnt4 could influence the stabilization of the epithelial state without reverting 
the mesenchymal one.  
Figure 25: Expression of Pax8 and Wnt4 in human thyroid cancer cells. 
qRT-PCR analysis was performed on total RNA prepared from human thyroid 
cells. As control, a pool of six normal thyroid tissues (N.T.) was used.  
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Moreover, to further study whether elevated levels of Wnt4 may have a role in 
cell migration, we performed wound healing assays comparing the cell 
mobility of BCPAP wild type cells and the pools of cells stable expressing 
Wnt4 or the empty vector as control. After 12 hours, the area of the wound was 
completely recovered by migrating cells in BcPAP cells and in the control 
pool. At difference, the motility of the cells stable expressing Wnt4 resulted 
strongly decreased, suggesting that Wnt4 over-expression significantly reduces 
the migration of human papillary thyroid tumors cells(Fgure 27).  
 
 
Figure 26: Effect of Wnt4 expression on EMT of human cancer thyroid cells. 
qRT-PCR analysis was performed on total RNA prepared from BcPAP pools of clones 
either expressing Wnt4 or transfected with the parental vector. The over-expression of 
Wnt4 is clearly responsible for the maintenance of the epithelial phenotype.  
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Figure 27: Wnt4 over-expression in human papillary thyroid tumor cells inhibits cellular migration. 
Wound healing migration assay for BcPAP, BcPAPpoolpCEFLpuro and BcPAPpoolWnt4 was 
performed. The healing of wounds by migrated cells at time O, 4, 8 and 12 h was imaged. 
BcPAPpoolWnt4 cells migrate slower than BcPAP and BcPAPpoolpCEFLpuro cells. 
BcPAPpool 
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5. Conclusions 
 
During thyroid development, Pax8 is expressed upon transition from 
undifferentiated endoderm cells to thyroid follicular fated cells in the thyroid 
anlage and continues to be expressed throughout development and in the adult 
gland (De Felice and Di Lauro 2004). It has been clearly demonstrated that 
Pax8 is necessary for the expression of thyroid-specific genes, like 
Thyroglobulin (Tg), Thyroperoxidase (TPO), and sodium/iodide symporter 
(NIS) essential for the syntesis of active thyroid hormones (Ohno et al. 1999; 
Pasca di Magliano et al. 2000; Zannini et al. 1992). In addition, Pax8
-/-
 mice 
have a barely visible thyroid gland that lacks the follicular cells (Mansouri et 
al. 1998). The critical role exerted by Pax8 in thyroid follicular cell 
differentiation has been demonstrated also in cell culture systems. For example, 
in thyroid cells expressing the polyoma virus middle T antigen (PCPy cells), 
loss of Pax8 expression results in loss of the thyroid-differentiated phenotype, 
measured as the expression of Tg, TPO and NIS genes. Re-introduction of 
Pax8 in PCPy cells is sufficient to reactivate the expression of the endogenous 
Tg, TPO and NIS genes (Pasca di Magliano et al. 2000). Given the pivotal role 
played by Pax8 in thyroid differentiation, many studies have been focused on 
the molecular mechanisms by which Pax8 modulates thyroid gene expression. 
The genome wide screening carried out in the lab where I performed my PhD 
programme aimed at the identification of new targets of the transcription factor 
Pax8 in rat thyroid differentiated cells FRTL-5. In the end, 2815 genes were 
found modulated 72 h after Pax8 RNAi; among the down-regulated genes there 
was Wnt4.  
Wnt4 is a secreted glycoprotein correlated and required for kidney 
tubulogenesis. Mice lacking Wnt4 activity fail to form pretubular cell 
aggregates. Moreover, Wnt4 appears to act as an autoinducer of the 
mesenchyme-to-epithelial transition that underlies nephron development (Stark 
et al. 1994). In thyroid, Wnt4 has been recently demonstrated to be a key 
player in Ras-mediated transformation of epithelial cells and to be involved in 
the inhibition of aberrant motility of neoplastic cells (De Menna et al. 2012). 
The results of this study indicate Wnt4 as new direct target of the transcription 
factor Pax8 and we demonstrated that Wnt4 has a thyroid-specific 
transcriptional activity suggesting that Pax8 has an important role in the 
modulation of Wnt4 gene expression. More in details, we demonstrated by 
EMSA experiments that there is a specific binding site responsible for Pax8 
binding to the Wnt4 promoter region and this site is very well conserved 
among the species. Furthermore, we revealed that in rat differentiated cells 
FRTL-5 Wnt4 is involved in the maintenance of the epithelial phenotype, in 
fact the EMT induced by the down-regulation of Wnt4 is completely reverted 
in the cellular model system that stable over-expresses Wnt4. This stable over-
expression of Wnt4 is also able revert the EMT mediated by the TGF-β1 
signaling.  
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We also revealed that, like Pax8, the expression of Wnt4 is strongly TSH-
dependent in FRTL-5 thyroid cells and is significantly reduced in human 
thyroid cancer cells.  
In conclusion, our data suggest that the over-expression of Wnt4 in human 
papillary cancer cells could influence the stabilization of the epithelial state and 
is necessary to reduce cellular migration. 
Moreover, the identification of Wnt4 as a novel target of the transcription 
factor Pax8 prompt us to hypothesize that its expression is associated with the 
fully differentiated state of the thyroid cells. 
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Summary
Background Congenital hypothyroidism (CH) is a common
endocrine disease that occurs in about 1:3000 newborns. In 80–
85% of the cases, CH is presumably secondary to thyroid dysgene-
sis (TD), a defect in the organogenesis of the gland leading to an
ectopic (30–45%), absent (agenesis, 35–40%) or hypoplastic (5%)
thyroid gland. The pathogenesis of TD is still largely unknown.
Most cases of TD are sporadic, although familial occurrences have
occasionally been described. Recently, mutations in the PAX8 tran-
scription factor have been identified in patients with TD.
Objective Our aim was to identify and functionally characterize
novel PAX8 mutations with autosomal dominant transmission
responsible for TD.
Design The PAX8 gene was sequenced in a mother and child both
suffering from congenital hypothyroidism (CH) because of thyroid
hypoplasia. Subsequently, expression vectors encoding the mutated
PAX8 were generated, and the effects of the mutation on both the
DNA-binding capability and the transcriptional activity were eval-
uated.
Results PAX8 gene sequencing revealed a heterozygous mutation
that consists of the substitution of a histidine residue with a gluta-
mine at position 55 of the PAX8 protein (H55Q). When tested in
cotransfection experiments with a thyroglobulin promoter reporter
construct, the mutant protein turned out to be still able to bind
DNA in Electrophoretic Mobility Shift Assay assays but transcrip-
tionally inactive.
Conclusions Our findings confirm the important role of PAX8 in
normal thyroid development and support the evidence that in
humans haploinsufficiency of PAX8 is associated with TD.
(Received 21 May 2010; returned for revision 13 June 2010; finally
revised on 13 July 2010; accepted 14 July 2010)
Introduction
Primary congenital hypothyroidism is a common endocrine dis-
ease in newborns, with an incidence of about 1:3000 live births,
and is characterized by elevated TSH levels at birth in response to
reduced thyroid hormone levels.1 In 85% of the cases, CH is
because of developmental anomalies of the thyroid gland (thyroid
dysgenesis, TD), which result in a thyroid gland that is absent
(thyroid agenesis or athyreosis), ectopically located (thyroid ecto-
py) or hypoplastic (thyroid hypoplasia).2 About 5% of the TD
cases are associated with mutations in the genes responsible for
thyroid development and growth,3 including genes that encode
for TTF-1/NKX2.1,4,5 FOXE1,6,7 PAX8,8,9 TSH receptor10 and
NKX2.5.11
PAX8, like other members of the Pax family, recognizes DNA
via a conserved 128-amino acid domain, the paired domain. The
gene maps to human chromosome 2q12-14 and contains a 4-Kb
transcription unit divided into 12 exons.12 PAX8 plays an impor-
tant role in thyroid development, when the thyroid bud invagi-
nates from the floor of the pharynx,13 and it is required both for
the morphogenesis of the thyroid gland9 and for the maintenance
of the thyroid-differentiated phenotype.14 In the adult thyroid,
PAX8 is essential for the transcriptional activation of the thyrop-
eroxidase (TPO), thyroglobulin (Tg) and sodium/symporter
(NIS) genes.15,16 Recently, it has been demonstrated that PAX8
and TTF-1/NKX2.1 biochemically associate and synergistically
activate transcription from the TPO17 and Tg gene promot-
ers.18,19 Homozygous Pax8 knockout mice die shortly after wean-
ing, presumably from severe hypothyroidism because of thyroid
hypoplasia, whereas heterozygotes were described unaffected.9
To date, eleven heterozygous inactivating mutations in the
PAX8 gene have been identified and characterized in patients
with TD.8,20,21 Only two of these mutations, the deletion in
exon 7 (c.989-992delACCC) located outside the paired domain22
and the p.S48F located within the paired domain,23 show
normal DNA-binding affinity but are transcriptionally inactive.
The remaining eight mutations already described are located
within the paired domain of PAX8 and result in a severe reduc-
tion in DNA binding. The autosomal dominant transmission is
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well established with variable degrees in the severity of
hypothyroidism.
In this study, we report the identification and functional charac-
terization of a novel PAX8 mutation in a mother and child with
CH because of thyroid hypoplasia. The mutation results in the sub-
stitution of histidine for glutamine at codon 55 of the PAX8 pro-
tein. Although the mutated residue is located within the paired
domain, the mutated protein does not display an impairment in
the DNA-binding activity but is unable to activate transcription
from known PAX8 target promoters.
Our results strengthen the notion that PAX8 mutation contrib-
utes to the sporadic and familial cases of CH.
Patients andmethods
Case reports
Two members of a nonconsanguineous family were diagnosed with
hypothyroidism (Fig. 1a). Patient II-1 was diagnosed as hypothy-
roidism at birth in the frame of a neonatal screening, displaying a
TSH level of 200 mU/ml (normal range: 1–10) and a low free T4 of
13 pmol/l (normal range: 20–30). The patient had no detectable
Thyroglobulin antibodies, and his serum TG was 160 lg/l (normal,
20–70). Thyroid 123I scintigraphy showed a hypoplastic gland in
normal position. Since birth he is receiving substitutive L-T4 treat-
ment. His physical and psychomotor development is normal.
Patient I-1, 24-year-old woman, is the mother of patient II-1.
During the CH screening, she was diagnosed as athyreotic but a
recent ultrasonography showed a hypoplastic thyroid (right lobe:
0Æ4 · 1Æ4 · 1Æ3 cm; left: 0Æ9 · 0Æ5 · 1Æ5 cm.) (Fig. 1a). She was
treated since birth and had normal development in terms of growth
and intelligence. Ultrasonography of the kidneys did not reveal any
structural abnormalities in the renal system. Her family history is
unknown, and unfortunately, the other members of the family did
not agree to provide DNA for the genetic studies.
DNA sequencing
All the coding region of the PAX8 gene was amplified as previously
described.8 PCR products were then purified with Antartic Phos-
phatase-Exonuclease I (New England BioLabs, Beverly, MA, USA)
at the following conditions: 37C for 15 min and 80C for 15 min,
respectively, and inactivation and then directly sequenced for
enzymes activation bidirectionally with a 377 ABI sequencer with
the same primers used for PCR amplification.
Plasmids
The plasmids were previously described and were as follows: CMV-
TTF-124 and pCMV5-H29a (also named PAX8-WT).12 The H55Q
and H55A mutations were introduced by site-directed mutagenesis
(QuikChange II-E Site-Directed Mutagenesis Kit; Stratagene, La
Jolla, CA, USA). All constructs were confirmed by sequencing. The
reporter plasmid TgCAT, originally named pTACAT-3, used in
transient transfection experiments was previously described.25
Cell culture and transfection
HeLa cells were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% foetal calf serum (Euroclone, Pero, MI,
Italy). For transient transfection experiments, cells were plated at
3 · 105 cells/60-mm tissue culture dish 5–8 h prior to transfection.
Transfections were carried out with the FuGENE6 (Roche Diagnos-
tics, Basel, CH, Switzerland) according to the manufacturer’s direc-
tions. The DNA/FuGENE ratio was 1:2 in all experiments. The
plasmid CMV-LUC was used as internal control in transfection
assays. Cells extracts were prepared after 48 h to determine either
the levels of CAT protein with a CAT enzyme-linked immunosor-
bent assay kit (Roche Diagnostics) or LUC activities by luciferase
assays as previously described.26 Transfection experiments were
carried out in duplicate and repeated at least three times. CAT
(a) (b)
(c)
Fig. 1 Identification of a novel PAX8 mutation.
(a) Pedigree of the family presenting with congeni-
tal hypothyroidism (CH) associated with the H55Q
mutation of PAX8 in the heterozygous state.
(b) Chromatogram of part of exon 3 of patients
showing a heterozygous T ﬁ G transversion at
nucleotide 165 of the paired domain PAX8
(c.165T>G). This mutation replaces a histidine
residue by glutamine (H55Q). (c) Schematic
representation of the paired domain (PD) and the
position of the H55Q mutation in a-helix 3 (a3).
The octapeptide (OP) and the residual paired-type
homeodomain (HD) are shown. Also, the previ-
ously identified PAX8 mutations are indicated by
asterisks.
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activity values on the graph are the means of all experiments (±)
SD. Statistical analysis uses two-tailed Student’s t-test to obtain the
P value associated with the observed fold of activation differences.
Protein production andWestern blot analysis
Wild-type and mutated PAX8 cDNA constructs were tran-
scribed and translated using the TnT Quick Coupled Tran-
scription/Translation System from Promega Corporation
(Madison, WI, USA). The level of transcription/translation
products and total extract of transfected Hela, prepared as pre-
viously described,27 were assessed by Western blot. For these
analysis, proteins were separated by SDS-10% PAGE, gel were
blotted onto Immobilon P (Millipore, Bredford, MA, USA) for
2 h, and the membranes were blocked in 5% nonfat dry milk
in Tris-buffered saline for 2 h before the addition of the anti-
PAX8 antibody (kindly provided by R. Di Lauro) for 1 h. The
filters were washed three times in Tris-buffered saline plus
0Æ5% Tween 20 before the addition of horseradish peroxidase–
conjugated secondary antibody for 45 min. Horseradish per-
oxidase was detected with ECL (GE Healthcare, Waukesha, WI,
USA).
EMSA
Double-stranded oligonucleotide C derived from the Tg promoter
was labelled with [c-32P] ATP and T4 polynucleotide kinase and
used as probe as previously described.16 The binding reactions were
incubated for 30 min at room temperature in a binding buffer con-
taining 10 mm HEPES (pH 7Æ9), 10% glycerol, 0Æ1 mm EDTA,
8 mm MgCl2, 1 mm dithiothreitol and 0Æ15 g/ml of poly (dI-dC).
DNA–protein complexes were resolved on a 5% nondenaturing
polyacrylamide gel and visualized by autoradiography.
Results
Sequencing of PAX8
In both affected members of the family (I-1 and II-1 in Fig. 1a),
sequence analysis of the PAX8 coding region gene revealed a het-
erozygous T ﬁ G transversion in exon 3 (Fig. 1b), resulting in the
substitution of a histidine at position 55, within the a-helix 3 of the
PAX8 paired domain, with a glutamine residue (PAX8-H55Q)
(Fig. 1b,c).
DNA-binding properties of the PAX8-H55Qmutant
To evaluate whether the PAX8-H55Q mutation produces a defect
in the DNA-binding ability of the PAX8 protein, we carried out
EMSA analysis with in vitro-translated PAX8 and PAX8-H55Q
proteins. As shown in Fig. 2a, the PAX8-H55Q mutant is able to
bind DNA similarly to wild-type PAX8 when challenged with the
oligo C derived from the Tg promoter and containing a well-
known PAX8-binding site. Equivalent amounts of each protein
were used in the EMSA assay reactions as confirmed by the Wes-
tern blot analysis (Fig. 2a). The same DNA-binding ability was
observed when total protein extracts of HeLa cells transiently
transfected with expression vectors encoding either the wild-type
or the mutated PAX8 protein were employed in the EMSA assay
(Fig. 2b). Also in this case, the amounts of each total extract used
in the binding reactions were normalized by Western blot
(Fig. 2b).
Therefore, our data indicate that the mutation of the histidine
residue within the paired domain does not affect the ability of
PAX8 to recognize its binding site on DNA, suggesting that the
H55 residue is not involved in contacts with DNA. To further con-
firm these results, we have generated an additional mutant, named
(a) (b) (d)(c)
Fig. 2 DNA binding of the PAX8-WT and PAX8 mutant proteins. The DNA-binding properties of PAX8-WT, PAX8-H55Q and PAX8-H55A mutants were
tested on a PAX8 response element, oligonucleotide C. EMSA were performed with in vitro-translated WT, H55Q and H55A mutant PAX8 proteins (a,c), and
protein extract prepared from HeLa cells transiently transfected with PAX8-WT, PAX8-H55Q and PAX8-H55A (b,c). PAX8-H55Q mutant (a, lane 3; b, lane
4; c, lane 3; d, lane 4) and PAX8-H55A mutant (c, lane 4; d, lane 5) are able to form a low-mobility complex with the oligo C as the PAX8-WT (a, lane 2; b, lane
3; c, lane 2; d, lane 3). No retarded band is present in the extract prepared from nontransfected HeLa cells used as a negative control (b and d, lane 2). The anal-
ysis by Western blotting of PAX8-WT, PAX8-H55Q and PAX8-H55A proteins showed that equivalent amounts of each protein were produced.
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PAX8-H55A, in which the histidine residue is substituted by an ala-
nine. The alanine is the substitution residue of choice that does not
alter the main-chain conformation,28 and it has been proven to be
unable to make contact with DNA. Consequently, we generated
this mutation to clarify whether the H55 residue of PAX8 is directly
involved in contacts with DNA or not. Specifically, if the H55 resi-
due is not involved in contacts with DNA, we expected that the
PAX8-H55A mutant did not show any impairment in DNA bind-
ing. Indeed, our results of the EMSA assays clearly indicated that
the PAX8-H55A mutant is able to bind to the PAX8-binding site
contained in the oligonucleotide C and shows no significant differ-
ences when compared to wild-type PAX8 and PAX8-H55Q
(Fig. 2c,d). The same results were obtained when in vitro-translated
proteins (Fig. 2c) or total extract of HeLa cells transiently transfect-
ed with either the wild-type or the mutated expression vectors
(Fig. 2d) were employed in EMSA assays. Western blotting of wild-
type and mutated proteins produced in vitro or transiently
expressed in HeLa cells revealed no difference in the synthesis effi-
ciency, indicating that the amino acid substitution does not cause
destabilization of the mutant proteins (Fig. 2c,d).
Transcriptional activity of PAX8-H55Qmutant
To evaluate the functional relevance of the H55Q mutation, we
relied on the ability of PAX8 to activate transcription from the thy-
roglobulin (Tg) promoter16 and we investigated the ability of the
PAX8-H55Q mutant to activate the transcription of a reporter gene
under the control of the Tg promoter. HeLa cells were transiently
transfected with expression vectors encoding wild-type PAX8 or
PAX8 mutants, together with a reporter construct in which the
minimal region of the Tg promoter is subcloned upstream of the
CAT gene (pTACAT325). In agreement with previous results,16,18
wild-type PAX8 is able to stimulate transcription from the Tg pro-
moter up to 7-fold, whereas PAX8-H55Q or PAX8-H55A shows a
significantly reduced Tg reporter activation (Fig. 3a). These results
led us to the conclusion that the PAX8-H55Q mutant has a signifi-
cant reduced ability to activate transcription despite the fact that it
has no impairment in DNA-binding activity.
Recently, it has been demonstrated that a physical interaction
between PAX8 and the transcription factor TTF-1/NKX2.1
underlies the synergistic effect of both factors on Tg promoter
(a)
(b)
Fig. 3 Functional analysis of PAX8-H55Q.
(a) HeLa cells were transiently transfected with the
reporter plasmid TgCAT (2 lg), the expression vec-
tor encoding PAX8-WT (100 ng), the PAX8-H55Q
mutant (100 ng) and the PAX8-H55A mutant
(100 ng). The protein levels of PAX8-WT, PAX8-
H55Q and PAX8-H55A after transfection were
measured by immunoblot and are shown. (b) HeLa
cells were transiently transfected with the reporter
plasmid TgCAT (2 lg) with or without the expres-
sion vectors encoding for TTF-1 (50 ng), PAX8-
WT (100 ng), PAX8-H55Q mutant (100 ng) and
PAX8-H55A mutant (100 ng). Folds of activation
are considered as ratio between values obtained
with and without cotransfection of the expression
vectors. CMV-LUC was added as internal reference
and all data were normalized to the ratio CAT/LUC
activity. Results are means ± SD from three inde-
pendent experiments, each performed in triplicate
transfection. Statistical analysis has been performed
by means of an unpaired two-tailed Student’s t-test
to obtain the P value associated with the observed
fold of activation differences (P < 0Æ1 and P < 0Æ05,
respectively).
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activation.18 To test whether the mutant PAX8-H55Q and TTF-1/
NKX2.1 could synergistically stimulate transcription from the Tg
promoter, we transiently cotransfected in HeLa cells the reporter
construct TgCAT together with the expression vectors encoding
wild-type PAX8, PAX8-H55Q, PAX8-H55A and TTF-1/NKX2.1
separately or in combination. Our data show that although the
activity of the PAX8-H55Q mutant is significantly lower than the
activity of wild-type PAX8, it can still display a robust synergism
with TTF-1/NKX2.1 in the transcriptional activation of the Tg pro-
moter (Fig. 3b). A similar behaviour was observed with the PAX8-
H55A mutant (Fig. 3b).
These results indicate that the H55Q mutation retains the ability
to functionally interact with TTF-1/NKX2.1.
Discussion
We have identified and functionally characterized a novel loss-of-
function mutation in the transcription factor PAX8, dominantly
inherited in two members of a family with severe thyroid hypopla-
sia. The mutation, a T ﬁ G transversion in exon 3 of the PAX8
gene, results in the substitution of a histidine at position 55 by a
glutamine residue (H55Q). Although the H55Q mutation is
located within the paired domain, we demonstrated that it does
not alter the DNA-binding ability of the mutant; however, it modi-
fies the functional properties of the protein. Our data are in agree-
ment with the results previously reported by Grasberg et al. for the
PAX8-S48F mutation,23 showing that the mutation, even if located
within the paired domain, abrogates the transactivation property
of PAX8 but not its DNA-binding ability.
Based on the crystal structure models of paired domain–DNA
complexes,29,30 histidine 55 of PAX8 is located in the a-helix 3 of the
paired domain and is predicted to make contacts with the DNA
backbone. However, this amino acid represents a variant residue,
being not conserved among the PAX genes.29 It is worth noting that
the structure of PAX8 bound to DNA has not been determined yet;
therefore, any assessment on the PAX8–DNA complex has been
made by comparison with other PAX homologues bound to DNA.31
Our hypothesis is that the H55Q mutation within helix 3 of the
paired domain is not involved in contacts with the DNA but might
affect the folding and the conformation of the C-terminal region of
PAX8, possibly of domains of the protein known to be crucial for
the transcriptional activity because involved in physical interactions
with other coactivators and/or the basal transcriptional machinery.
This hypothesis is supported by the observation that also the PAX8-
H55A mutation that we have generated retains the ability to bind
DNA but is not able to efficiently activate transcription, as it hap-
pens with PAX8-H55Q. Because the alanine residue has a small side
chain, the substitution of the histidine residue by alanine should
severely interfere with the DNA recognition and consequently show
an impairment in the DNA binding of PAX8-H55A. However, our
results demonstrated that such a mutation affects only the transacti-
vation property of PAX8. Hence, the H55Q mutation represents,
together with the previously reported S48F mutation,23 a new type
of PAX8 mutations responsible for congenital hypothyroidism.
PAX8 is a major gene in the regulation of the thyroid-differenti-
ated phenotype14 and plays an important role in the morphogene-
sis of thyroid gland.9 To date, all PAX8 gene mutations reported
are located within the paired domain except for one mutation
c.989-992delACCC,22 located in exon 7 outside the paired domain
that cause a frameshift with a premature stop codon after codon
277. The PAX8/277del protein retains the DNA-binding ability but
it is not capable of activating transcription, thus indicating that the
C-terminal region is essential for PAX8 transcriptional activity.
Recently, it has been demonstrated that PAX8 activity can be mod-
ulated by the interaction with other proteins, forming complexes
on regulatory regions of target genes.18,27,32 Therefore, our findings
suggest that the PAX8-H55Q mutant does not efficiently activate
transcription because it does not allow the recruitment of other fac-
tors or coactivators to the target promoters. Furthermore, it has
been demonstrated that PAX8 co-operates with the transcription
factor TTF-1/NKX2.1,17,19 and our laboratory specifically demon-
strated that PAX8 and TTF-1/NKX2.1 form a functional hetero-
complex responsible for the synergistic transcriptional activation
of the Tg promoter in differentiated thyroid cells.18 The relevance
of this interaction has been further confirmed by the analysis of the
in vivo mouse model bearing a partial deficiency of Ttf1 and Pax8
genes. The double heterozygous null mice show thyroid dysgenesis,
a phenotype that is completely absent in either of the single hetero-
zygous mice.33 Our results demonstrate that the PAX8-H55Q
mutant is still able to synergize with TTF-1/NKX2.1 on the Tg pro-
moter, as indicated by the significantly higher stimulation of the
reporter gene expression in cells expressing both PAX8-H55Q and
TTF-1/NKX2.1, suggesting that the H55 residue is not essential for
the functional interaction with TTF-1/NKX2.1. Therefore, it will be
of interest to further investigate the effect of this novel mutation
with respect to the already described interactions that PAX8 makes
with other partners.
The mutation here reported in the child was inherited from his
mother, in line with the dominant model of inheritance proposed
for the cases of familial thyroid dysgenesis caused by PAX8 muta-
tions.8,34 The present case, as the others previously published, dem-
onstrates that loss-of-function mutations of PAX8 are
symptomatic in heterozygotes in humans, whereas only homozy-
gous mice for a targeted disruption of Pax8 display severe hypothy-
roidism, characterized by absence or dramatic reduction in the
thyroid gland.9 Haploinsufficiency, monoallelic expression,
imprinting, dominant negative properties8,34 and stochastic
expression of the PAX alleles, as noted for Pax5,35 are the molecular
mechanism that could lead to disturbed thyroid development in
humans. The patients reported here carry the H55Q mutation and
both present CH with thyroid hypoplasia.
In conclusion, the novel PAX8-H55Q mutation identified in
patients with congenital hypothyroidism and thyroid hypoplasia
confirms the role of PAX8 in normal thyroid development and
might be helpful to better understand the role of PAX8 in the path-
ogenesis of thyroid dysgenesis.
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